

# 20 YEARS CANCER INCIDENCE IN OMAN REPORT 1996-2015



Department of Non-Communicable Diseases Directorate General of Primary Health Care




See the difference

# MAKE OVERALL SURVIVAL PERSONAL

### As a 1<sup>st</sup> line treatment in RAS wild-type Metastatic colorectal cancer

 Median overall survival of 33.1 months with ERBITUX<sup>®</sup> plus FOLFIRI versus 25.6 months with bevacizumab plus FOLFIRI<sup>1\*</sup>

1-Stintzing S et al. ECC 2013. Abstract no. E17-7073. 2. Ciardiello F et al. ASCO 2014. Abstract no. 3506. Identifying code: 2014-05-EENS-9JWMZU









Now available on www.moh.gov.om

# 20 YEARS OF CANCER INCIDENCE IN OMAN 1996-2015





Department of Non-Communicable Diseases Directorate General of Primary Health Care This report is printed for the first time. Comments and suggestions concerning its contents are encouraged and could be sent to

Department of Non-Communicable Diseases Directorate General of Primary Health Care P. O. Box 393 Postal Code 100 Muscat, Minstry of Health

> Tel. +968 24946378 Fax +968 24946379 Email : mohdncd@gmail.com

#### **ACKNOWLEDGMENTS**

The Oman National Cancer Registry would like to acknowledge and appreciate all those who were involved in contributing to this report. The Report idea and conceptualization was by Dr. Bassim Al-Bahrani, senior consultant oncologist, from the National Oncology Center, whom we thank and are grateful for his guidance and support.

The Report was prepared by and formatted by Dr. Najla A. Al-Lawati, Head of Non-communicable Diseases Surveillance (NCD) Section, and contribution from the Registry staff namely Mr. Nabil Al-Siyabi, Mr. Dhahi Al- Gharbi and Mr. Salim Al Wehaibi.

We greatly appreciate the contribution of the Report reviewers, mainly by Dr. Shadha Al-Raisi, Director of NCD and Dr. Jawad Al-Lawati, Senior Consultant at Ministry of Health.

#### FORWORD

The Oman National Cancer Registry was established as a hospital-based registry in 1985. In 1996, the registry began functioning as a population-based registry and since then, cancer incidence reports have been published annually. The latest report, the 2015 cancer incidence report was published in October 2018.

The registry continues to play an important role for policy makers in setting priorities for the prevention and control of cancer in Oman and it does so by providing a database that monitors cancer patterns in the country as well as evaluating trends in incidence of all types of cancer overtime.

The "20 Year of Cancer Incidence in Oman 1996-2015." marks the 20th anniversary since the first cancer incidence report was published in Oman in 1996 and it is yet another product of the hard work and dedication by the cancer registry team in the department of Non-communicable disease under the Directorate General of Primary Health Care. It presents the overall incidence of cancer in Oman over a 20-year period and describes the most common types of cancer diagnosed between 1996 and 2015. Coinciding with this report, the Oman Medical Journal also published an editorial and a supplement which mirrors similar data succinctly.

Dr. Said Al-Lamki MD, MPH, MTQM, FFPH Director General of Primary Healthcare

#### PREFACE

Cancer is a significant public health problem in both developed and developing countries. The global burden of cancer is estimated in 2018 to be 18.1 million new cancer cases. It is the second leading cause of death globally and was responsible for an estimated 1 in 6 deaths (9.6 million deaths in 2018) is due to cancer.

The Department of Non-Communicable Diseases is delighted to introduce this comprehensive report of cancer incidence in Oman over twenty years of data. It is the first report on trends of cancer in Oman its release coincides with the 20th anniversary since the release of the first incidence report in Oman.

This report presents cancer trends over 20 years and the five most common cancer among Omanis during that period as well as in two different periods of ten years. Over 20 years breast cancer was the leading cancer among Omanis followed by Non-Hodgkin lymphoma (NHL), leukemia, colorectal and thyroid cancers. Also, tables were added to demonstrate the distribution of cancer cases by gender for each governorate in Oman and the five most common cancer among them.

We hope that the information delivered in this report will help to provide insights and serve as a reference to all those working in reducing the burden of cancer in oman. Above all, we hope it will serve as a guide for researchers and academics interested in conducting more epidemiological studies on cancer. I should not miss the opportunity to express my gratitude to all colleagues working in all Ministry of Health facilities and other governmental institutions who have contributed to this report during the past years. We fully appreciate their contributions and without their cooperation the publication of this report would have not been possible .

Dr. Bassim Al Bahrani, MD, FRACP, FRCP(Glasg),PhD Deputy Chairperson, National Cancer Control Committee Sr. Consultant Oncologist, National Oncology Center

#### MINISTERIAL DECISION NO. 222/ 2017 ON REGISTRATION OF CANCER CASES

Based on the Royal Decree No. 36/ 2014 on determining the terms of reference of the Ministry of Health and the approval of its organizational structure, and The Ministerial Decision No. 4/ 2001 on Notification of Cancer Cases, and for the public interest, the following have been decided:

**Article (1):** The following neoplasms are considered cancerous diseases or carcinoma in-situ numbered as per the 10th revision of the International Statistical Classification of Diseases & Related Health Problems (ICD-10):

- Malignant Neoplasms (C00-C79)
- In Situ Neoplasms (D00-D09)
- Neoplasms of Uncertain or Unknown Behaviour (D37- D48)

**Article (2):** If a person is clinically or surgically or laboratory diagnosed with cancer or suspected of having cancer or carcinoma in-situ, it should be reported to the Oman National Cancer Registry at the Non-communicable Diseases Department in the Directorate General of Primary Health Care on the attached form within (30) days from the date of diagnosis.

Article (3): Reporting of cancer cases mentioned in the aforesaid Article shall be the responsibility of the following:-

- a. The doctor who has examined the patient
- b. The technician of the laboratory where the sample was confirmed positive
- c. The Director or Head of the government health institution (Civil or Military) or private health institutions, in which the case was diagnosed.

**Article (4):** Recording of persons with cancer or suspected cases in the Oman National Cancer Registry shall be according to the disease classification and shall include their trinomial name, tribe name, surname, age, sex, nationality and addresses.

**Article (5):** The Oman National Cancer Registry records are confidential, no persons other than the Registry workers are allowed to view or disclose them except on the grounds of the public interest.

**Article (6):** The Ministerial Decision No. 4/2001 shall be cancelled and all that contravenes with this Decision or contradicts with its provision shall be cancelled.

Article (7): This Decision shall come into effect from the date of its issue, and shall be implemented by the competent each in his respective field of specialization. Issued on: 21/03/1439H Corresponding to: 10/12/2017

Dr. Ahmed bin Mohammed bin Obaid Al Saidi Minister of Health

### **PUBLICATION 1996 - 2005**



### **PUBLICATION 2006 - 2015**



# CONTENTS

Acknowledgments	3
Foreword	4
Preface	5
Ministerial Decision	6
BACKGROUND OF THE SULTANATE OF OMAN	11
Geographical Feature	12
Population Structure	13
OMAN NATIONAL CANCER REGISTRY	15
Objectives of Oman Cancer Registry	15
METHODS	15
1. Data Collection	15
2. Data Coding, Entry and Validity Checks	16
3. Completeness of Data Reporting	16
4. Data Analysis	17
5. Definitions	17
Comparison between the cancer incidence of 1996 and 2015	19
Trends of Cancer Incidence in Oman 1996-2015	23
Cancer Incidence in Oman, 1996 - 2015 (Overall results)	27
Regional Distribution	35
Common Cancers among Omanis, 1996-2015	37
MOST COMMON CANCERS IN MALES	51
1. Prostate Cancer	52
2. Stomach Cancer	53
3. Non-Hodgkin Lymphoma	54
4. Leukemia	55
5. Colorectal Cancer	56
MOST COMMON CANCERS IN FEMALES	57
1. Breast Cancer	58
2. Thyroid Cancer	59
3. Colorectal Cancer	60
4. Non-Hodgkin Lymphoma	61
5. Leukemia	62
DISTRIBUTION OF CANCER BY GOVERNORATES	63



#### **Geographical Features**

The Sultanate of Oman is located in the southeastern corner of the Arabian Peninsula. It has a coastal line extending almost 1,700 kilometers from the Strait of Hormuz in the north to the borders of the Republic of Yemen, overlooking three seas; the Arabian Gulf, The Sea of Oman and the Arabian Sea. The country borders Saudi Arabia and United Arab Emirates (UAE) in the West, the Republic of Yemen in the South, the Strait of Hormuz in the North and the Arabian Sea in the East. There are a number of scattered Omani islands in the Arabian Sea; the most important are Masirah and Al-Halaniyat.

The total area of the Sultanate of Oman is approximately 309,500 square kilometers and it is the second largest country in the Arabian Peninsula. The Sultanate is composed of varying topographic areas consisting of plains, wadis (dry river beds) and mountains. The most important area is the plain overlooking the Sea of Oman and the Arabian Sea with an area of about 3% of the total area. The mountain ranges occupy almost 15% of the total land of Oman and are inhabited by about 5% of the population. The remaining area is mainly sand, wadis and desert (about 82% of the total area). The climate differs from one area to another; it is hot and humid in the coastal areas in summer, hot and dry in the interior with the exception of higher mountains and Dhofar Governorate, which enjoy a moderate climate throughout the year.

The Sultanate of Oman is administratively divided into 11 Governorates with 62 Wilayats. These are: Muscat, Dhofar, Musandam Ad Dakhliyah, Al Buraymi, Ash Sharqiyah, Al Batinah, Adh Dhahirah, and Al Wusta. The Governorates of Ash Sharqiyah and Batinah have each been further subdivided into two, giving a total of eleven governorates (Figure 1).

#### **Population Structure**

The estimated mid-year population in1996 was 2,135,853 of which 1,593,769 were Omanis and 542,084 were Non-Omanis (Table 1). The Omani population shows a sex ratio of 963 females per 1000 males. About 16% of the population was under-5 years and 45% is under-15 years. Only 3.0% of the total Omani population were above the age of 65 years (Figure 2).

In contrast, the estimated mid-year population in 2015 was 4,159,102 of which 2,344,946 were Omanis and 1,814,156 were Non-Omanis (Table 2). The Omani population showed a sex ratio of 979 females per 1000 males. About 14.8% of the population were under-5 years and 35.7% were under-15 years. Only 4.3% of the total Omani population were above the age of 65 years (Figure 3).

#### Figure 1: Diagrammatic Presentation of the Sulthanate of Oman





Table T. Ayes		inani i upulai				
Age	Ма	le	Fem	ale	Tot	al
Group	Number	%	Number	%	Number	%
0 - 4	128,210	15.8	121,350	15.5	249,560	15.7
5 - 9	134,350	16.5	130,540	16.7	264,890	16.6
10 - 14	132,190	16.2	127,770	16.3	259,960	16.3
15 - 19	108,010	13.3	102,780	13.1	210,790	13.2
20 – 24	72,820	9	67,090	8.6	139,910	8.8
25 – 29	47,570	5.9	44,510	5.7	92,080	5.8
30 – 34	35,440	4.4	35,850	4.6	71,290	4.5
35 – 39	29,930	3.7	32,910	4.2	62,840	3.9
40 - 44	25,640	3.2	28,070	3.6	53,710	3.4
45 – 49	21,690	2.7	21,410	2.7	43,100	2.7
50 – 54	21,390	2.6	20,590	2.6	41,980	2.6
55 – 59	16,580	2.0	14,710	1.9	31,290	2.0
60 - 64	13,560	1.7	10,990	1.4	24,550	1.5
65 – 69	10,240	1.3	8,530	1.1	18,770	1.2
70 – 74	5,790	0.7	5,800	0.7	11,590	0.7
75 +	8,380	1.0	9,110	1.2	17,490	1.1
Total	811,790	100.00	782,010	100.00	1,593,800	100.00

#### Table 1 : Age structure of the Omani Population, 1996


 Table 2 : Age structure of the Omani Population, 2015

Age	Mal	e	Fem	ale	Tot	al
Group	Number	%	Number	%	Number	%
0 - 4	177,581	15.0	170,838	14.7	348,419	14.9
5 - 9	138,659	11.7	133,650	11.5	272,309	11.6
10 - 14	110,210	9.3	106,717	9.2	216,927	9.3
15 - 19	111,304	9.4	106,727	9.2	218,031	9.3
20 – 24	126,416	10.7	122,550	10.5	248,966	10.6
25 – 29	122,755	10.4	119,615	10.3	242,370	10.3
30 – 34	105,329	8.9	103,401	8.9	208,730	8.9
35 – 39	79,084	6.7	79,049	6.8	158,133	6.7
40 – 44	52,717	4.5	49,738	4.3	102,455	4.4
45 – 49	36,091	3.0	36,147	3.1	72,238	3.1
50 – 54	30,919	2.6	31,886	2.7	62,805	2.7
55 – 59	24,938	2.1	28,611	2.5	53,549	2.2
60 - 64	18,067	1.5	21,086	1.8	39,153	1.7
65 – 69	15,301	1.3	16,392	1.4	31,693	1.4
70 – 74	12,912	1.1	13,125	1.1	26,037	1.1
75 +	22,147	1.9	20,984	1.8	43,131	1.8
Total	1,184,430	100.00	1,160,516	100.00	2,344,946	100.00

#### Figure 2: Population pyramid, Oman, 1996



#### Figure 3: Population pyramid, Oman, 2015



### **REGISTRY METHODS**

#### **Oman National Cancer Registry**

The Oman National Cancer Registry was established in 1985 as a hospital-based registry. Only cases treated in tertiary hospitals were registered. In 1996, with the establishment of the Department of Non-Communicable Diseases Surveillance and Control, the registry was transferred and started functioning under the under Directorate General of Health Affairs and later the Directorate General of Primary Health Care . New cancer notification forms were developed and distributed to all regional hospitals and sister institutions. In the year 2000, the registration form was simplified, printed and distributed to all institutions that could potentially report cancer cases. Three trained cancer registrars are responsible for data collection, coding and data entry.

#### **Objectives and Functions of the Cancer Registry**

- 1. To compile an accurate database on the incident cases of cancer in The Sultanate of Oman.
- 2. To monitor trends of cancer which can guide policy makers in setting priorities for control and management of cancer.
- 3. To provide researchers and clinicians with population–based information on the number and types of cancer cases and their geographical distribution within the Sultanate of Oman.

#### **Methods**

1. Data Collection

#### a) Active Collection

Active data collection involves the registry personnel visiting different sources where cancer is diagnosed and abstracting data on Cancer Registry Forms. Being the largest tertiary center for diagnosis and treatment of cancer, registrars visit the Royal Hospital twice a week and abstract data on the notification forms. Similarly, other tertiary hospitals like Khoula Hospital and Al-Nahhda Hospital are visited once a month.

Data of patients undergoing chemotherapy and radiotherapy treatments are also collected from the National Oncology Centre which was established within the Royal Hospital in November 2004. Data of patients diagnosed with cancer abroad are traced through oncology out-patient registers at the National Oncology Centre and subsequently, data are extracted from their case notes. Detailed list of patients sent abroad for cancer treatment through the Ministry of Health system are obtained from the Department of Treatment Abroad.

### **METHODS**

#### **b)** Passive Reporting

Cancer notification was made mandatory in the year 2001 through a Ministerial Decision (4/2001). When a case of cancer is diagnosed, the attending physician of the relevant specialty or the medical records department at the regional hospital completes the notification forms and sends them to the registry. Other institutions like the Armed Forces Hospital and Sultan Qaboos University Hospital have similar passive reporting. In 2017, a Ministerial Decision updated to (222/2017) include all the health institution (civil or military) and private health facilities. These institutions are frequently visited by the cancer registrars for data extraction of patients diagnosed in them.

#### 2. Data-Coding, Entry and Validity Checks

Until 2001 were coded using the edition the all cancer cases second 0f International Classification of Diseases for Oncology (ICDO-2) with topography 'C' and morphology 'M' codes. Data were entered in CanReg 3 programme, supplied by the International Agency for Research on Cancer (IARC), Lyon, France. CanReg 4 software programme and International Classification of Diseases for Oncology ICDO-3 were used from 2003. This programme has a duplicate entry checking facility, which prevents the same case being registered more than once. In 2016, registration software was upgraded to CanReg 5.00.40. For this report we used CanReg 5.00. Validity checks are performed for consistency between items: site/histology, gender/site and age/site/histology combinations by CanReg 5.00.

#### 3. Completeness of Data Reporting

Data were obtained from all hospitals with histopathology/cytology and hematology laboratories (The Royal, Al-Nahdha, Khoula, Sultan Qaboos and Sohar Hospitals) from copies of reports of patients diagnosed with cancer to the registry. Since the mid of 2001, the Sultan Qaboos University and Armed Forces Hospitals histopathology laboratories have also started sending reports of cancer cases diagnosed in their laboratories.

Since the establishment of the new National Oncology Center in November 2004, the chemotherapy and radiotherapy lists are also obtained once a week from the relevant departments.

Monthly hospital "admission–discharge" lists were sent from the tertiary hospitals. From 2003, similar lists were sent by all the regional hospitals as well. These lists help in updating the registry and in updating the status of the patient (deceased or alive). The list of patients with cancer on chemotherapy are obtained from tertiary hospitals. Details of missing data are sought from all of the above sources so that the registry can be updated.

### **METHODS**

#### 4. Data Analysis

Data is first checked for consistency and validity using (Canreg-5.00.40 build1566), the International Agency for Research on Cancer (IARC), 2008 software. Frequency distribution and incidence tables are generated for Omanis only. Data for individual cancers are then exported in csv form to Stata software (version 14.2, Stata Corporation, TX, USA) for analysis of incidence by region, gender and morphological types. Bar diagrams and graphs are made using Microsoft excel version 2013 (Microsoft Corporation).

Population denominators used for the calculations of incidence rates (by 5- year age group, gender and region) were obtained from Ministry of Health's Annual Health Reports. Since the 2003 report, we have included four comprehensive tables showing the frequency as well as the incidence of cancers by site, from the year 1996 onwards.

# 5. Definitions : The following definitions have been used for the calculation of frequency and incidence rate of cancer presented in this report

#### Incidence

The number of new cancer cases in a defined population within a specific time period.

#### Date of Diagnosis

The date documented on the histopathology report. For clinical cases, the date of diagnosis is the date stated in patient's case notes to have cancer.

#### **Population at Risk**

Individuals who are susceptible to specific cancers.

#### Crude incidence rate(CR)

The number of new cancer cases in the population occurring within a Gregorian calendar (1st January to 31st December) divided by the population at risk in the same period expressed per 100,000 population.

#### Age-specific incidence rate

Incidence rate in a specific age group.

#### Multiple primaries

Two or more abnormal growths of tissue occurring simultaneously. The neoplasms are histologically different and may be found in the same or different sites.

#### Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and/or visceral organs.

### **METHODS**

#### Carcinoma in situ

A group of abnormal cells that remain in the place where they first formed. They have not spread.

#### Age-standardized rate (ASR)

Age standardization is necessary when comparing several populations that differ with respect to age. Hence the World Standard Population of Segi, (Table 2) (Segi M.Cancer mortality for selected sites in 24 countries (1950-57). Sendai: Tohuku University, School of Medicine, 1960) was used to adjust the crude incidence rates and to remove the confounding effect of age. Therefore, the age-adjusted rates (ASR) could be used for comparison purposes with other rates where the same world standard population was used, especially those issued by the World Health Organization's agency, the International Agency for Research on Cancer (IARC), in its periodic publication, Cancer Incidence in Five Continents.

er ale frend etalladiar op	anation of orgi, about for rig
Age Structure	Population
00-04	12,000
05-09	10,000
10-14	9,000
15-19	9,000
20-24	8,000
25-29	8,000
30-34	6,000
35-39	6,000
40-44	6,000
45-49	6,000
50-54	5,000
55-59	4,000
60-64	4,000
65-69	3,000
70-74	2,000
75+	2,000
Total	100,000

Table 3: Age Structure of the World Standard Population of Segi, used for Age -adjustment

### COMPARISON

#### Comparison between the cancer incidence of 1996 and 2015

In 1996, the total registered cases among Omanis were 787(445 males, 342 females), and the crude incidence rates for all cancer among Omanis was 49.4 per 100,000 (54.8 per 100,000 for males and 43.7 per 100,000 for females). The age standardized rate, adjusted to the world standard population, was 95 per 100,000 (106.1 per 100,000 for males and 82.8 per 100,000 for females).


While, in 2015, the total registered cases among Omanis were 1,632 (760 males, 872 females) and the crude incidence rates for all cancer among Omanis was 69.7 per 100,000 (64.2 per 100,000 for males and 75.1 per 100,000 for females). The age standardized rate, adjusted to the world standard population, was 105 per 100,000 (101 per 100,000 for males and 109 per 100,000 for females).

Gender	Frequency	Percentage (%)	CR	ASR
		1996		
Male	445	56.5	54.8	106.1
Female	342	43.5	43.7	82.8
Total	787	100	49.4	95.0
		2015		
Male	760	46.6	46.2	101
Female	872	53.4	75.1	109
Total	1,632	100	69.7	105

Table 4: Distribution of Cancer Cases among Omanis by Gender (1996 & 2015)


### **COMPARISON**





If we consider the crude rate of 49.37 per 100,000 people for 1996 to continue at same rate then it would be expected the total cases in 2015 would be 1,158 cases. However, the total cases were 1,632 cases which means that the incidence rate has increased. There was a rise in the crude incidence rate by 41% between 1996 and 2015. But this increase was the highest in the last 5 years. Between 2010 and 2015 the crude incidence has increased by 37.9% compared to 2.3% increase in the period 1996-2010 (figure 5).

Figure 5: Crude incidence rate 1996-2015



### COMPARISON

There is a true increase in the incidence of cancer in Oman which may be due to the following reasons. The population size has increased and the population pyramid in Oman has shown concentration at the base with more population at younger age groups. However, the picture is changing. For example, in 1996 about 16% of the population were under-5 years and 45% were under-15 years and only 3.0 % of the total Omani population were above the age of 65 years. While in 2015 about 14.9% of the population were under-5 years and 35.7% were under-15 years. Only 4.3% of the total Omani population are above the age of 65 years.

As the population ages and because cancer is a disease of older people, the risk of cancer will rise rapidly. The life expectancy in Oman has increased from 72 in 1996 to 76.4 in 2015. This rise in cancer incidence cases may be attributed to a number of factors, mainly the advancement of health care services, with the introduction of an early detection program for breast cancer and the advancement in diagnostic and treatment modalities. Public awareness of the disease has increased due to efforts of the Oman Cancer Association and the introduction of the mammogram mobile unit. Other factors that might explain the increase in the incidence rates are the rapid socioeconomic changes resulting in an increase in unhealthy habits of tobacco use, sedentary life styles and increase uptake of unhealthy food habits.



# TRENDS OF CANCER INCIDENCE IN OMAN 1996 – 2015



### **TRENDS OF CANCER**

#### Cancer incidence in Oman, 1996-2015

Between January 1996 and December 2015, there were 21,002 newly diagnosed cases of cancer among the Omani population with an average of 1,050 cases per year, of which 10,723 (55.1%) were males and 10,279 (48.9%) were females.

The average annual crude rate for all cancer among Omanis was 56.4 per 100,000 (55.1 per 100,000 for males and 54.2 per 100,000 for females). The average ASR was 125.7 per 100,000 (105.2 per 100,000 for males and 96.3 per 100,000 for females). The frequencies and incidence rates of cancers in Omani male and female are presented in Table 5.

Overall, there was an observed gradual decline in the trend of average annual ASRs for Omani male over the 20-year period. On the other hand, the trend of average annual ASRs for Omani females increased gradually over the same period (Figure 6).

The average annual age-specific incidence rates were observed to increase dramatically with advancing age in both sexes (Figure 7).

Gender	Frequency	Percentage (%)	Average annual	Average annual
			crude rate	ASR
Male	10,723	51.1	55.1	105.2
Female	10,279	48.9	54.2	96.3
Total	21,002	100	56.4	125.7

Table 5: Distribution of Cancer Cases among Omanis by Gender, 1996-2015

### **TRENDS OF CANCER**




Figure : 6 Age-adjusted Incidence Rates of Cancers among Omanis by Year, 1996-2015

Figure : 7 Average Annual Age-Specific Incidence Rates of Cancers by gender, 1996-2015




Table 6 and 7 illustrate the frequency of incidence cases per age group in Omani male and female for the period 1996-2015. While table 8 and 9 demonstrate Age – Adjusted incidence Rates in Omani males and females for the same period. Additionally, table 10 and 11 show the frequency of Incident Cases in Omanis by years, from 1996 to 2015 for males and females respectively. Whereas, table 12 and 13 display the Age – Adjusted incidence Rates in Omani nationals by year, from 1996 to 2015 male and female respectively.

### Table 6: Frequency of Incident Cases in Omani Males, 1996-2015

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	24	0	0	0	0	0	0	0	0	2	0	2	2	3	2	2	5	6	0.2	C00
Tongue	101	0	0	0	0	0	3	0	5	2	10	19	20	12	15	3	3	9	1	C01-02
Mouth	114	0	0	0	0	1	3	2	4	9	12	12	13	11	17	10	10	10	1.1	C03-06
Salivary glands	36	0	0	0	2	0	4	1	1	4	2	1	3	3	8	1	3	3	0.3	C07-08
Tonsil	13	0	0	0	0	0	0	0	1	1	2	1	2	2	3	0	0	1	0.1	C09
Other oropharynx	22	0	1	0	0	0	0	1	0	0	3	1	3	4	2	3	2	2	0.2	C10
Nasopharynx	101	0	0	2	2	7	9	7	3	7	11	18	8	10	5	8	3	1	1	C11
	28	0	2	1	0	1	0	2	1	1	0		4			2	1	1	0.3	C12-13
Hypopharynx Bhanary unspecified	10	0	0	0	0	0	0	2	0	0	1	4	4	4	4	1	2	1	0.3	C14
Pharynx unspecified																				
Oesophagus	209	0	0	0	0	0	0	2	0	1	7	13	19	15	43	32	35	42	2	C15
Stomach	960	0	0	0	0	2	4	2	18	21	37	52	84	100	190	126	156	168	9.3	C16
Small intestine	43	0	0	0	0	0	0	0	2	2	4	1	4	5	11	4	7	3	0.4	C17
Colon	473	0	0	1	1	3	7	18	25	36	42	53	65	51	58	49	28	36	4.6	C18
Rectum	301	0	0	0	0	1	10	9	15	12	18	24	40	32	48	36	27	29	2.9	C19-20
Anus	45	0	0	0	0	0	0	0	1	1	4	7	5	7	7	1	4	8	0.4	C21
Liver	544	0	10	3	2	1	4	6	6	10	26	32	60	85	102	69	66	62	5.3	C22
Gallbladder etc.	76	0	0	0	0	0	0	0	1	3	3	7	9	12	10	8	11	12	0.7	C23-24
Pancreas	209	0	0	0	0	0	0	2	1	4	11	14	30	24	34	33	24	32	2	C25
Nose, sinuses etc.	31	0	0	0	1	2	2	0	2	0	2	4	6	1	2	3	2	4	0.3	C30-31
Larynx	130	0	0	0	0	0	0	0	3	5	11	14	22	12	19	14	13	17	1.3	C32
Trachea, bronchus and lung	720	0	0	0	2	0	3	7	5	14	28	44	81	81	149	101	108	97	7	C33-34
Other thoracic organs	39	0	1	1	0	1	3	3	0	4	0	1	4	2	6	1	4	8	0.4	C37-38
Bone	147	0	5	14	27	26	18	12	7	9	3	3	5	2	9	3	2	2	1.4	C40-41
Melanoma of skin	42	0	0	2	1	0	0	1	1	1	1	4	5	4	7	5	5	5	0.4	C43
Other skin	434	0	3	4	4	3	8	12	10	12	15	23	31	43	63	60	66	77	4.2	C44
Mesothelioma	18	0	0	0	0	0	0	0	0	0	1	0	3	3	1	3	3	4	0.2	C45
Kaposi sarcoma	57	0	0	1	0	2	3	5	5	6	2	4	6	5	6	4	5	3	0.6	C46
Connective and soft tissue	175	0	17	14	12	18	20	14	7	10	7	8	12	11	8	6	2	9	1.7	C47,C49
Breast	99	0	0	0	0	0	0	2	1	7	7	13	12	15	15	7	7	13	1	C50
Penis	6	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	2	0.1	C60
Prostate	998	0	1	0	2	2	0	0	1	4	7	17	52	94	196	182	199	241	9.7	C61
Testis	120	0	13	2	0	10	25	23	15	11	9	3	2	3	0	1	1	2	1.2	C62
Other male genital organs	5	0	0	0	0	0	1	0	1	1	0	0	0	0	1	0	0	1	0	C63
Kidney	236	0	27	6	3	1	3	9	7	14	18	20	30	15	25	23	15	20	2.3	C64
Renal pelvis	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	0	C65
Ureter	4	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0	C66
Bladder	590	0	3	1	1	1	2	6	10	24	19	35	62	61	89	83	79	114	5.7	C67
Other urinary organs	6	0	1	0	0	0	0	0	0	0	0	0	2	0	1	1	1	0	0.1	C68
Eye	52	0	15	1	0	2	2	0	1	2	2	1	2	5	7	2	7	3	0.5	C69
Brain, nervous system	404	0	51	42	31	26	21	19	23	24	18	26	32	25	21	18	17	10	3.9	C70-72
Thyroid	242	0	0	0	2	9	21	29	30	20	22	22	18	17	25	12	7	8	2.4	C73
Adrenal gland	46	0	30	3	3	0	1	2	0	0	0	0	3	2	0	1	1	0	0.4	C74
Other endocrine	10	0	1	1	0	1	1	0	0	2	1	1	1	0	0	0	1	0	0.1	C75
Hodgkin disease	384	0	11	43	39	39	42	30	34	28	14	27	26	14	11	10	4	12	3.7	C81
Non-Hodgkin lymphoma	932	0	28	43	25	48	42	53	44	52	64	67	80	78	87	74	4 80	73	9.1	C82-85,C96
		0	28	42	25	48	37 0	0	44	52 1		0	80	2	0		0			
Immunoproliferative diseases	5										0					0		2	0	C88
Multiple myeloma	177	0	0	0	0	1	1	4	2	0	6	12	23	28	33	22	20	25	1.7	C90
Lymphoid leukaemia	443	0	104	88	49	52	24	9	12	4	10	13	17	5	19	13	13	11	4.3	C91
Myeloid leukaemia	320	0	38	13	10	18	19	24	19	25	18	18	21	12	23	20	16	26	3.1	C92-94
Leukaemia unspecified	80	0	9	7	9	12	8	2	5	2	2	2	5	8	4	2	2	1	0.8	C95
Myeloproliferative disorders	15	0	0	1	0	0	0	1	1	1	0	2	1	3	1	1	1	2	0.1	MPD
Myelodysplastic syndromes	5	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0	0	1	0	MDS
Other and unspecified	438	0	16	3	3	6	2	12	9	14	22	26	46	49	73	47	63	47	4.3	0&U
All sites	10723	0	388	296	231	296	312	331	339	413	502	674	986	982	1465	1110	1131	1267	104	ALL
All sites but C44	10289	0	385	292	227	293	304	319	329	401	487	651	955	939	1402	1050	1065	1190	100	ALLbC44

### Table 7: Frequency of Incident Cases in Omani Females, 1996-2015

	ALL AGES	AGE UNK		-	10	45		05		05	10	45	50			05	70	75	(0)	105 (1011)
SITE			0-	5-	10-	15- 0	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)
Lip	12 50	0	1	0	1	0	0	0	0 3	1	1	1 9	1	1	1	1	1	2	0.1	C00 C01-02
Tongue	64	0	0	0	0	1	0	1	2	4	4	9 3	13	5	5 14	4	4	2	0.6	C03-06
Salivary glands	43	0	1	1	0	3	6	3	2	4	4	2	8	3	2	1	4	0	0.6	C03-08
Tonsil	43	0	0	0	0	0	0	0	0	4	4	2	0	0	2	0	0	0	0.4	C09
Other oropharynx	7	0	0	0	0	0	0	0	1	0	0	1	1	1	0	2	0	1	0.1	C10
Nasopharynx	48	0	0	0	0	5	4	2	4	7	8	6	5	2	1	1	2	1	0.5	C11
Hypopharynx	17	0	0	0	0	0	0	0	0	2	4	1	0	1	3	0	4	2	0.2	C12-13
Pharynx unspecified	5	0	0	0	0	0	0	0	0	2	0	1	0	0	1	0	0	1	0.1	C14
Oesophagus	134	0	0	0	0	0	0	1	1	2	3	4	13	11	30	16	23	30	1.3	C15
Stomach	512	0	0	1	1	1	10	3	13	20	37	40	71	62	88	50	62	53	5.1	C16
Small intestine	28	0	0	0	0	0	0	1	0	0	3	4	2	2	3	2	7	4	0.3	C17
Colon	376	0	0	0	3	4	8	12	19	23	28	38	51	40	57	28	24	41	3.8	C18
Rectum	232	0	0	0	0	1	3	5	12	21	27	15	31	34	25	21	23	14	2.3	C19-20
Anus	23	0	0	0	0	0	0	1	0	2	1	0	5	3	2	1	5	3	0.2	C21
Liver	245	0	8	0	1	1	4	3	5	7	9	18	39	32	41	29	25	23	2.5	C22
Gallbladder etc.	90	0	0	0	0	0	0	0	2	4	11	8	9	10	17	11	10	8	0.9	C23-24
Pancreas	126	0	0	0	0	0	1	1	2	3	6	10	19	18	31	8	13	14	1.3	C25
Nose, sinuses etc.	23	0	1	0	1	1	0	0	2	1	0	4	1	3	3	1	3	2	0.2	C30-31
Larynx	29	0	0	0	0	0	0	1	1	1	6	0	2	5	3	4	3	3	0.2	C32
Trachea, bronchus and lung	229	0	1	0	0	1	1	3	4	9	8	13	32	29	39	29	27	33	2.3	C33-34
Other thoracic organs	18	0	8	0	0	1	0	1	1	0	2	0	1	1	1	0	0	2	0.2	C37-38
Bone	94	0	2	7	23	18	10	10	3	3	3	2	8	1	1	0	0	3	0.9	C40-41
Melanoma of skin	34	0	0	0	1	0	0	4	2	1	3	4	6	1	3	2	4	3	0.3	C43
Other skin	332	0	1	3	1	6	2	10	7	. 11	20	29	32	40	42	36	38	54	3.3	C44
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	C45
Kaposi sarcoma	17	0	0	0	0	0	0	0	0	1	6	0	0	3	3	2	1	1	0.2	C46
Connective and soft tissue	120	0	27	4	9	7	7	10	7	6	9	12	4	5	2	1	3	7	1.2	010
Breast	2181	0	0	0	0	2	25	95	184	275	290	297	309	229	175	109	89	102	21.9	C50
Vulva	24	0	0	0	0	0	1	0	0	1	2	2	1	3	4	1	5	4	0.2	C51
Vagina	30	0	1	0	0	1	0	2	0	1	1	2	5	1	5	7	1	3	0.3	C52
Cervix uteri	550	0	0	0	0	0	1	10	28	53	68	71	73	61	64	32	52	37	5.5	C53
Corpus uteri	206	0	0	0	1	0	1	3	7	9	15	18	24	27	45	24	18	14	2.1	C54
Uterus unspecified	86	0	1	0	0	0	0	2	4	8	8	13	10	8	11	6	8	7	0.9	C55
Ovary	463	0	1	4	15	27	35	33	27	15	36	40	44	37	48	28	40	33	4.7	C56
Other female genital organs	10	0	0	0	0	1	0	1	0	1	1	3	0	1	0	1	1	0	0.1	C57
Placenta	23	0	0	0	0	1	2	6	3	1	3	4	2	1	0	0	0	0	0.2	C58
Kidney	204	0	40	7	3	2	4	7	10	11	9	12	28	16	20	18	8	9	2.1	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	C65
Ureter	4	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	1	0	C66
Bladder	204	0	2	0	0	1	2	6	6	1	11	16	12	21	27	28	24	47	2.1	C67
Other urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	C68
Eye	45	0	20	4	1	2	0	0	1	1	2	1	2	0	4	0	3	4	0.5	C69
Brain, nervous system	281	0	36	34	28	24	18	16	14	14	16	19	17	13	16	6	4	6	2.8	C70-72
Thyroid	1035	0	0	3	7	47	106	145	150	133	113	108	74	40	45	19	30	15	10.4	C73
Adrenal gland	42	0	24	5	0	1	2	2	1	2	1	1	1	1	0	1	0	0	0.4	C74
Other endocrine	3	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	225	0	4	17	21	22	30	23	15	7	13	16	7	18	13	7	7	5	2.3	C81
Non-Hodgkin lymphoma	601	0	27	27	16	23	32	40	28	29	33	43	64	48	83	35	30	43	6	C82-85,C96
Immunoproliferative diseases	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	C88
Multiple myeloma	123	0	0	0	0	0	0	0	1	3	4	6	22	14	25	18	13	17	1.2	C90
Lymphoid leukaemia	275	0	101	53	27	13	9	9	7	1	6	7	6	4	10	6	9	7	2.8	C91
Myeloid leukaemia	244	0	16	11	18	24	17	15	18	16	16	15	16	12	18	10	13	9	2.5	C92-94
Leukaemia unspecified	77	0	14	10	14	5	4	2	1	2	4	1	1	3	5	4	2	5	0.8	C95
Myeloproliferative disorders	7	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	4	0	0.1	MPD
Myelodysplastic syndromes	5	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	0	2	0.1	MDS
Other and unspecified	410	0	17	3	2	9	4	9	13	22	30	32	50	29	53	42	54	41	4.1	0&U
All sites	10279	0	354	196	195	258	350	500	613	745	890	956	1130	907	1090	662	703	730	103	ALL
All sites but C44	9947	0	353	193	195	252	348	490	606	734	870	927	1098	867	1030	626	665	676	100	ALLbC44
, 5105 But 077	5571		000	100	104	202	040	700	000	7.04	010	321	1030	507	10-10	020	000	010	100	MELUU44

### Table 8: Age – Adjusted incidence Rates in Omani Males, 1996-2015

matrixmatr	SITE	ALL	AGE	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE	(%)	CUM	CUM	ASR	ICD (10th)
map		AGES	UNK																	RATE		0-64	0-74		
AndAn																					0.2				
bb </td <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td>																					1				
bar <td></td>																									
math <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>2.6</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			-	-	-		-									2.6									
math <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>																1									
																					0.2				
matrix m																									
					-																				
Bandame         Ba         Ba        Ba        Ba        B																									
			-				-																		
bic         bic <td></td>																									
michandomichand 9 0 <					-	-																			
b         b																									
Image     Image    <																			48.3						
Maxamarian     42     82 <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td>4</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>					-							-				-			4						
Ohesion         isingle         isingle <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																									
Meter																									
Network         Network <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																									
Ormethy and point both         O																									
Pineta     9     0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>												1													
Penden6888 <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td>-</td> <td></td>			-									1			-										
Product900 </td <td></td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>												0							1						
Tesh100											-								120						
DemandependiationantSSS												1.3													
Normal         Normal<																									
Amapoine         4         5         6        6         6         6 </td <td></td> <td></td> <td></td> <td>1</td> <td></td> <td>-</td> <td></td> <td></td> <td></td>				1																		-			
Uter4888<			-	0																					
Inder5000 <td></td>																									
Other					0		0		0.3		2.6		6.7		16.5				56.8						
Feq526364 <td></td>																									
Add         Add <td></td> <td></td> <td></td> <td></td> <td>0</td> <td></td> <td>0.1</td> <td></td> <td>0</td> <td></td> <td>0.2</td> <td></td> <td></td> <td></td> <td>1.4</td> <td></td>					0		0.1		0		0.2				1.4										
Typicit929.9		404	0	1.9	1.7	1.2	1	0.9	1	1.7	2.6	2.6	5	7.2	6.8	6.8	7.7	10.5	5	2.08	3.9	0.2	0.29	2.9	C70-72
Adrenal gland       46       8.       1.1       0.1							0.4		1.6				4.2												
Other endormine1000 <td></td> <td></td> <td></td> <td></td> <td>0.1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.7</td> <td></td>					0.1									0.7											
Hodgkin disease38400.41.81.61.61.61.62.63.2.65.85.83.83.64.32.66.11.70.10.210																									
Non-Hodgkin lymphoma       932       0       1.1       1.7       1       1.9       1.6       2.9       3.3       5.5       9.2       1.8       1.1       2.1       2.3       3.5       9.1       2.8       3.5       9.1       2.8       3.5       9.1       2.8       1.5       9.1       2.8       3.5       9.1       2.8       1.5       9.1       2.8       1.5       9.1       0.5 <td>Hodgkin disease</td> <td></td> <td></td> <td></td> <td>1.8</td> <td>1.6</td> <td>1.5</td> <td>1.8</td> <td>1.6</td> <td>2.6</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>3.6</td> <td>4.3</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Hodgkin disease				1.8	1.6	1.5	1.8	1.6	2.6						3.6	4.3								
Immunoprofilerative diseases       5       0 <th< td=""><td>•</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>5.5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	•										5.5														
Multiper myelona       177       0.7 <td></td> <td></td> <td></td> <td></td> <td></td> <td>0</td> <td></td>						0																			
Lymphoid leukaemia       443       0       4       3.6       2       2.1       1       0.5       0.9       0.4       1.4       2.5       3.8       1.4       6.2       5.5       8       5.5       2.28       4.3       0.15       0.22       2.6       691         Myeloid leukaemia       320       0       1.5       0.5       1.4       0.5       0.4       1.4       2.5       3.8       1.4       6.2       5.5       8.5       9.28       4.3       0.15       0.22       2.6       691         Myeloid leukaemia       320       0       1.5       0.4       0.7       0.8       1.4       2.5       3.4       4.7       3.2       7.5       8.5       9.9       1.4       3.1       0.15       0.22       2.5       0.99       1.4       0.1       0.4       0.4       0.4       0.4       0.4       0.4       0.5       0.4       1.4       0					0	0	0		0.2				2.3			10.7	9.4		12.4						
Leukaemia unspecified       80       0.       0.3       0.3       0.4       0.5       0.3       0.1       0.4       0.2       0.3       0.4       1.1       2.2       1.3       0.9       1.2       0.5       0.4       0.8       0.04       0.05       0.	Lymphoid leukaemia	443	0	4	3.6	2	2.1	1	0.5	0.9	0.4	1.4	2.5	3.8	1.4	6.2	5.5	8	5.5	2.28	4.3	0.15	0.22	2.6	C91
Myeloproliferative disorders         15         0 <th0< td=""><td>Myeloid leukaemia</td><td>320</td><td>0</td><td>1.5</td><td>0.5</td><td>0.4</td><td>0.7</td><td>0.8</td><td>1.3</td><td>1.4</td><td>2.7</td><td>2.6</td><td>3.4</td><td>4.7</td><td>3.2</td><td>7.5</td><td>8.5</td><td>9.9</td><td>12.9</td><td>1.64</td><td>3.1</td><td>0.15</td><td>0.25</td><td>2.5</td><td>C92-94</td></th0<>	Myeloid leukaemia	320	0	1.5	0.5	0.4	0.7	0.8	1.3	1.4	2.7	2.6	3.4	4.7	3.2	7.5	8.5	9.9	12.9	1.64	3.1	0.15	0.25	2.5	C92-94
Myeloproliferative disorders         15         0 <th0< td=""><td></td><td>80</td><td></td><td></td><td></td><td>0.4</td><td></td><td>0.3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.41</td><td></td><td>0.04</td><td></td><td></td><td>C95</td></th0<>		80				0.4		0.3												0.41		0.04			C95
Other and unspecified       438       0       0.6       0.1       0.1       0.2       0.1       0.7       0.7       1.5       3.2       5       10.3       13.3       23.8       20       38.9       23.4       2.25       4.3       0.3       0.59       4.6       0.8U         All sites       10723       0       14.8       12       9.2       11.7       13.5       18       25.7       43.9       72.5       129       222       266       477       473       699       631       55.1       104       6.57       12.43       105       ALL		15	0	0		0		0		0.1	0.1	0	0.4		0.8	0.3	0.4				0.1	0.01	0.02		MPD
All sites 10723 0 14.8 12 9.2 11.7 13.5 18 25.7 43.9 72.5 129 222 266 477 473 699 631 55.1 104 6.57 12.43 105 ALL	Myelodysplastic syndromes	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0	0.5	0.03	0	0	0	0	MDS
	Other and unspecified	438	0	0.6	0.1	0.1	0.2	0.1	0.7	0.7	1.5	3.2	5	10.3	13.3	23.8	20	38.9	23.4	2.25	4.3	0.3	0.59	4.6	0&U
All sites but C44 10289 0 14.7 11.9 9.1 11.6 13.1 17.3 24.9 42.6 70.3 125 215 254 457 447 658 593 52.9 100 6.33 11.85 101 ALLbC44	All sites	10723	0	14.8	12	9.2	11.7	13.5	18	25.7	43.9	72.5	129	222	266	477	473	699	631	55.1	104	6.57	12.43	105	ALL
	All sites but C44	10289	0	14.7	11.9	9.1	11.6	13.1	17.3	24.9	42.6	70.3	125	215	254	457	447	658	593	52.9	100	6.33	11.85	101	ALLbC44

### Table 9: Age – Adjusted Incidence Rates in Omani Females, 1996-2015

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	12	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.3	0.4	0.5	0.7	1	0.06	0.1	0.04	0.01	0.1	(1001) C00
Tongue	50	0	0	0	0	0	0	0.1	0.2	0.4	0.6	1.6	1.3	1.9	1.8	1.9	2	1	0.26	0.5	0.04	0.06	0.5	C01-02
Mouth	64	0	0	0	0	0	0	0.1	0.2	0.3	0.4	0.5	2.8	1.4	4.9	3.4	2.7	4	0.34	0.6	0.05	0.08	0.7	C03-06
Salivary glands	43	0	0	0	0	0.1	0.3	0.2	0.2	0.4	0.6	0.4	1.7	0.8	0.7	0.5	0.7	0.5	0.23	0.4	0.03	0.03	0.3	C07-08
Tonsil	45 0	0	0	0	0	0.1	0.5	0.2	0.2	0.4	0.0	0.4	0	0.0	0.7	0.5	0.7	0.5	0.23	0.4	0.05	0.05	0.5	C09
Other oropharynx	7	0	0	0	0	0	0	0	0.1	0	0	0.2	0.2	0.3	0	1	0	0.5	0.04	0.1	0	0.01	0.1	C10
Nasopharynx	48	0	0	0	0	0.2	0.2	0.1	0.1	0.7	1.1	1.1	1.1	0.5	0.4	0.5	1.3	0.5	0.25	0.5	0.03	0.04	0.4	C11
	17	0	0	0	0	0.2	0.2	0.1	0.5	0.2	0.6	0.2	0	0.3	1.1	0.5	2.7	1	0.09	0.2	0.03	0.04	0.4	C12-13
Hypopharynx Pharynx unspecified	5	0	0	0	0	0	0	0	0	0.2	0.0	0.2	0	0.5	0.4	0	0	0.5	0.03	0.2	0.01	0.02	0.2	C14
Oesophagus	134	0	0	0	0	0	0	0.1	0.1	0.2	0.4	0.2	2.8	3	10.4	7.7	15.2	14.9	0.03	1.3	0.09	0.2	1.6	C15
Stomach	512	0	0	0	0	0	0.4	0.1	1	2.1	5.1	7.2	15.2	3 16.7	31	24	41.1	26.3	2.7	5.1	0.09	0.2	5.7	C16
Small intestine		0	0	0	0	0	0.4		0	0			0.4		1.1	1	41.1	20.3	0.15		0.4			C17
Colon	28	0	0	0	-			0.1			0.4 3.9	0.7	10.9	0.5 10.8	20.1	10.5		20.4	1.98	0.3 3.8	0.02	0.04 0.44	0.3	C18
Rectum	376 232	0	0	0	0.1	0.2 0	0.4 0.1	0.7	1.5 0.9	2.4 2.2	3.5	6.8 2.7	6.6	9.2	8.8	13.5 10.1	15.9 15.2	20.4	1.22	2.3	0.29	0.44	3.9 2.4	C19-20
	232	0	0	0	0	0	0.1	0.3	0.9	0.2		0	1.1	0.8				1.5			0.01	0.03		C21
Anus	23	0		0	0	0		0.1	0.4		0.1				0.7	0.5	3.3	1.5	0.12	0.2 2.5	0.19		0.3	
Liver			0.3		-		0.2			0.7	1.2	3.2	8.4	8.6	14.5	13.9	16.6	11.4	1.29			0.34	2.7	C22
Gallbladder etc.	90	0	0	0	0	0	0	0	0.2	0.4	1.5	1.4	1.9	2.7	6	5.3	6.6	4	0.47	0.9	0.07	0.13	1	C23-24
Pancreas	126	0	0	0	0	0	0	0.1	0.2	0.3	0.8	1.8	4.1	4.9	10.9	3.8	8.6	7	0.66	1.3	0.12	0.18	1.5	C25
Nose, sinuses etc.	23	0	0	0	0	0	0	0	0.2	0.1	0	0.7	0.2	0.8	1.1	0.5	2	1	0.12	0.2	0.02	0.03	0.2	C30-31
Larynx	29	0	0	0	0	0	0	0.1	0.1	0.1	0.8	0	0.4	1.4	1.1	1.9	2	1.5	0.15	0.3	0.02	0.04	0.3	C32
Trachea, bronchus and lung	229	0	0	0	0	0	0	0.2	0.3	1	1.1	2.3	6.9	7.8	13.7	13.9	17.9	16.4	1.21	2.3	0.17	0.33	2.6	C33-34
Other thoracic organs	18	0	0.3	0	0	0	0	0.1	0.1	0	0.3	0	0.2	0.3	0.4	0	0	1	0.09	0.2	0.01	0.01	0.1	C37-38
Bone	94	0	0.1	0.3	1	0.7	0.4	0.6	0.2	0.3	0.4	0.4	1.7	0.3	0.4	0	0	1.5	0.5	0.9	0.03	0.03	0.5	C40-41
Melanoma of skin	34	0	0	0	0	0	0	0.2	0.2	0.1	0.4	0.7	1.3	0.3	1.1	1	2.7	1.5	0.18	0.3	0.02	0.04	0.3	C43
Other skin	332	0	0	0.1	0	0.2	0.1	0.6	0.5	1.2	2.8	5.2	6.9	10.8	14.8	17.3	25.2	26.8	1.75	3.3	0.22	0.43	3.6	C44
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.5	0	0.5	0.02	0	0	0	0	C45
Kaposi sarcoma	17	0	0	0	0	0	0	0	0	0.1	0.8	0	0	0.8	1.1	1	0.7	0.5	0.09	0.2	0.01	0.02	0.2	C46
Connective and soft tissue	120	0	1.1	0.2	0.4	0.3	0.3	0.6	0.5	0.6	1.2	2.2	0.9	1.4	0.7	0.5	2	3.5	0.63	1.2	0.05	0.06	0.8	C47,C4
Breast	2181	0	0	0	0	0.1	1.1	5.3	14.1	29.3	40.2	53.3	66.2	61.8	61.7	52.4	59	50.7	11.5	21.9	1.67	2.22	20.8	C50
Vulva	24	0	0	0	0	0	0	0	0	0.1	0.3	0.4	0.2	0.8	1.4	0.5	3.3	2	0.13	0.2	0.02	0.04	0.3	C51
Vagina	30	0	0	0	0	0	0	0.1	0	0.1	0.1	0.4	1.1	0.3	1.8	3.4	0.7	1.5	0.16	0.3	0.02	0.04	0.3	C52
Cervix uteri	550	0	0	0	0	0	0	0.6	2.2	5.6	9.4	12.7	15.6	16.5	22.6	15.4	34.5	18.4	2.9	5.5	0.43	0.68	5.7	C53
Corpus uteri	206	0	0	0	0	0	0	0.2	0.5	1	2.1	3.2	5.1	7.3	15.9	11.5	11.9	7	1.09	2.1	0.18	0.29	2.3	C54
Uterus unspecified	86	0	0	0	0	0	0	0.1	0.3	0.9	1.1	2.3	2.1	2.2	3.9	2.9	5.3	3.5	0.45	0.9	0.06	0.11	0.9	C55
Ovary	463	0	0	0.2	0.6	1.1	1.6	1.8	2.1	1.6	5	7.2	9.4	10	16.9	13.5	26.5	16.4	2.44	4.7	0.29	0.49	4.2	C56
Other female genital organs	10	0	0	0	0	0	0	0.1	0	0.1	0.1	0.5	0	0.3	0	0.5	0.7	0	0.05	0.1	0.01	0.01	0.1	C57
Placenta	23	0	0	0	0	0	0.1	0.3	0.2	0.1	0.4	0.7	0.4	0.3	0	0	0	0	0.12	0.2	0.01	0.01	0.2	C58
Kidney	204	0	1.6	0.3	0.1	0.1	0.2	0.4	0.8	1.2	1.2	2.2	6	4.3	7	8.6	5.3	4.5	1.08	2.1	0.13	0.2	1.8	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0.01	0	0	0	0	C65
Ureter	4	0	0	0	0	0	0	0	0	0	0.1	0	0.2	0	0	0	0.7	0.5	0.02	0	0	0.01	0	C66
Bladder	204	0	0.1	0	0	0	0.1	0.3	0.5	0.1	1.5	2.9	2.6	5.7	9.5	13.5	15.9	23.3	1.08	2.1	0.12	0.26	2.3	C67
Other urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.7	0	0.01	0	0	0	0	C68
Eye	45	0	0.8	0.2	0	0.1	0	0	0.1	0.1	0.3	0.2	0.4	0	1.4	0	2	2	0.24	0.5	0.02	0.03	0.3	C69
Brain, nervous system	281	0	1.4	1.4	1.2	1	0.8	0.9	1.1	1.5	2.2	3.4	3.6	3.5	5.6	2.9	2.7	3	1.48	2.8	0.14	0.17	1.9	C70-72
Thyroid	1035	0	0	0.1	0.3	1.9	4.8	8.1	11.5	14.2	15.7	19.4	15.9	10.8	15.9	9.1	19.9	7.5	5.46	10.4	0.59	0.74	7.6	C73
Adrenal gland	42	0	1	0.2	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.3	0	0.5	0	0	0.22	0.4	0.01	0.01	0.2	C74
Other endocrine	3	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0.02	0	0	0	0	C75
Hodgkin disease	225	0	0.2	0.7	0.9	0.9	1.3	1.3	1.2	0.7	1.8	2.9	1.5	4.9	4.6	3.4	4.6	2.5	1.19	2.3	0.11	0.15	1.6	C81
Non-Hodgkin lymphoma	601	0	1.1	1.1	0.7	0.9	1.4	2.2	2.2	3.1	4.6	7.7	13.7	13	29.3	16.8	19.9	21.4	3.17	6	0.4	0.59	5.4	C82-5,C
Immunoproliferative diseases	3	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0.5	0.02	0	0	0	0	C88
Multiple myeloma	123	0	0	0	0	0	0	0	0.1	0.3	0.6	1.1	4.7	3.8	8.8	8.6	8.6	8.4	0.65	1.2	0.1	0.18	1.5	C90
Lymphoid leukaemia	275	0	4	2.2	1.1	0.5	0.4	0.5	0.5	0.1	0.8	1.3	1.3	1.1	3.5	2.9	6	3.5	1.45	2.8	0.09	0.13	1.6	C91
Myeloid leukaemia	244	0	0.6	0.5	0.7	1	0.8	0.8	1.4	1.7	2.2	2.7	3.4	3.2	6.3	4.8	8.6	4.5	1.29	2.5	0.13	0.19	1.8	C92-94
Leukaemia unspecified	77	0	0.6	0.4	0.6	0.2	0.2	0.1	0.1	0.2	0.6	0.2	0.2	0.8	1.8	1.9	1.3	2.5	0.41	0.8	0.03	0.05	0.5	C95
Myeloproliferative disorders	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0.5	2.7	0	0.04	0.1	0	0.02	0.1	MPD
Myelodysplastic syndromes	5	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	1	0.03	0.1	0	0	0	MDS
Other and unspecified	410	0	0.7	0.1	0.1	0.4	0.2	0.5	1	2.3	4.2	5.7	10.7	7.8	18.7	20.2	35.8	20.4	2.16	4.1	0.26	0.54	4.3	0&U
All sites	10279	0	14.1	8.3	8.1	10.6	15.7	27.8	47.1	79.3	124	172	242	245	384	318	466	363	54.2	103	6.89	10.8	96.3	ALL
								-				-	-											

### Table 10: Frequency of Incident Cases in Omani Males by year, 1996-2015

CITE	1006	1007	1009	1000	2000	2001	2002	2002	2004	2005	2006	2007	2008	2000	2010	2011	2012	2012	2014	2015	
SITE	1996	1997 2	1998 2	1999 2	2000 2	2001	2002	2003 0	2004 2	2005	2006 2	2007 0	2008	2009 0	2010	2011 2	2012	2013 2	2014 0	2015 0	ICD (10th) C00
	5	4	1	5	6	3	3	4	4	4	6	5	4	3	4	4	4	12	6	14	C01-02
Tongue		4					7							8							
Mouth Salivary glands	6		6	5	3	3		4	10	7	2	5	6		3	8	7	5	10	5	C03-06
	2	1	6	0	1	1	2		5	0	0	1	2	1	2	0	2	2	2	5	C07-08
Tonsil	0	1	0	1	0	1	0	0	1	1	2	2	1	0	1	0	0	1	0	1	C09
Other oropharynx	0	0	0	0	2	0	0	3	3	3	2	0	1	1	1	2	0	1	1	2	C10
Nasopharynx	5	8	4	2	7	7	3	3	7	4	2	4	6	6	5	4	2	3	9	10	C11
Hypopharynx	2	1	1	2	1	1	4	1	8	0	0	0	1	3	0	0	0	0	1	2	C12-13
Pharynx unspecified	1	1	0	0	0	0	0	1	1	0	0	1	0	1	0	1	0	1	1	1	C14
Oesophagus	13	11	10	10	10	11	12	9	9	12	11	9	5	8	15	10	10	10	15	9	C15
Stomach	43	53	50	56	56	57	54	35	34	54	43	36	33	50	32	58	64	55	54	43	C16
Small intestine	1	1	1	1	1	2	3	0	0	2	0	2	0	2	2	5	3	3	4	10	C17
Colon	11	11	15	6	14	12	14	15	17	23	23	21	19	22	32	36	45	45	43	49	C18
Rectum	6	13	9	9	6	13	8	15	6	17	14	11	10	19	10	26	26	26	24	33	C19-20
Anus	3	0	1	3	1	5	4	3	2	1	1	2	2	1	1	3	4	4	2	2	C21
Liver	22	16	31	35	28	30	13	20	26	34	18	20	30	18	19	29	34	29	51	41	C22
Gallbladder etc.	0	3	2	4	5	2	3	3	3	7	2	7	3	4	5	7	2	5	3	6	C23-24
Pancreas	9	11	5	6	10	13	2	6	12	7	6	5	8	10	14	16	16	22	13	18	C25
Nose, sinuses etc.	1	2	1	3	2	0	0	2	5	2	3	3	1	1	1	3	0	0	0	1	C30-31
Larynx	7	5	10	4	5	2	2	7	8	10	10	6	4	4	12	7	7	8	5	7	C32
Trachea, bronchus and lung	28	49	32	50	37	- 44	30	29	31	30	30	40	28	30	25	44	31	42	48	42	C33-34
Other thoracic organs	4	3	1	1	3	3	1	1	2	1	3	1	1	3	0	5	0	2	3	1	C37-38
	4	8	6		4	3	6	7	10	10	1		4				9	2	9	8	C40-41
Bone			1	5		3		1	4	10	0	5		11 4	13	16					
Melanoma of skin	2	3		0	1		2					2	2		2	3	2	4	2	2	C43
Other skin	29	27	22	13	15	17	27	19	18	17	17	22	23	25	20	22	25	32	22	22	C44
Mesothelioma	0	0	1	2	1	1	0	1	0	0	1	1	1	0	0	4	1	1	2	1	C45
Kaposi sarcoma	3	8	0	5	1	2	5	4	0	2	4	3	2	2	2	7	1	4	0	2	C46
Connective and soft tissue	10	11	11	6	14	8	7	8	13	6	4	3	8	4	10	6	9	8	11	18	C47,C49
Breast	2	4	3	3	3	6	5	5	3	7	6	4	1	5	8	6	8	5	10	5	C50
Penis	0	1	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	1	1	C60
Prostate	39	47	41	45	37	45	32	30	26	40	29	54	41	48	48	66	82	82	81	85	C61
Testis	4	3	4	3	2	5	6	5	7	3	6	6	7	6	7	10	6	7	10	13	C62
Other male genital organs	0	0	0	0	0	0	0	0	2	0	0	0	1	1	0	0	0	0	0	1	C63
Kidney	7	8	5	8	13	6	7	16	6	12	6	5	7	18	21	14	15	16	26	20	C64
Renal pelvis	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	1	C65
Ureter	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	1	C66
Bladder	32	28	23	26	17	19	19	21	19	28	27	33	25	26	35	35	35	48	53	42	C67
Other urinary organs	0	0	1	1	1	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	C68
Eye	7	3	5	3	2	2	0	4	5	4	2	5	2	1	0	3	1	1	0	2	C69
Brain, nervous system	17	22	26	16	18	29	17	21	27	17	10	14	14	23	18	20	28	18	28	21	C70-72
Thyroid	8	10	5	8	5	14	11	15	8	10	6	6	12	13	3	12	17	19	31	29	C73
Adrenal gland	0	1	0	1	1	14	0	3	2	2	3	1	0	3	6	4	6	4	3	5	C74
											3										
Other endocrine	0	1	0	1	0	1	0	0	1	0		1	0	1	0	0	0	1	2	0	C75
Hodgkin disease	11	15	20	18	18	21	18	19	22	14	20	11	18	17	17	23	27	21	25	29	C81
Non-Hodgkin lymphoma	45	43	40	43	42	38	37	51	49	43	41	43	44	41	41	57	53	54	61	66	C82-85,C96
Immunoproliferative diseases	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	C88
Multiple myeloma	5	14	8	7	10	9	6	4	9	12	4	10	9	8	9	7	13	13	10	10	C90
Lymphoid leukaemia	12	19	19	19	18	20	22	23	28	22	17	12	26	31	24	37	15	18	34	27	C91
Myeloid leukaemia	6	9	15	10	14	14	12	21	10	14	20	20	17	14	14	27	18	17	19	29	C92-94
Leukaemia unspecified	7	3	5	5	4	7	12	6	6	3	1	5	2	1	3	2	2	5	1	0	C95
Myeloproliferative disorders	0	0	1	1	0	0	1	1	0	1	1	3	1	1	2	1	0	0	0	1	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	1	MDS
Other and unspecified	23	32	28	24	29	25	27	20	27	19	21	23	17	21	13	26	23	17	8	15	0&U
÷			479	478	470	510	446	467	498	508	432	475						681	745	760	
All sites	445	520	4/9	4/0					430	000	432	4/0	452	520	504	679	655	001		/00	ALL

### Table 11: Frequency of Incident Cases in Omani Females by year, 1996-2015

OITE	1000	1007	1000	1000	2000	2004	2000	2002	2004	2005	0000	0007	2002	2000	2010	2011	2010	2010	2014	2015	ICD (10th)
SITE	1996 0	1997 0	1998 1	1999 0	2000 0	2001 0	2002 0	2003 1	2004 2	2005 0	2006	2007	2008 2	2009 0	2010 0	2011 0	2012 2	2013 0	2014 0	2015 2	ICD (10th) COO
							1			1	1										
Tongue	6	1	0	4	2	0	1	2	2	1	1	2	2	2	4	4	3	1	6	6	C01-02
Mouth	1	7	1	4	2	2	1	3	2	2	1	5	3	5	4	3	3	5	7	3	C03-06
Salivary glands	0	1	2	2	1	2	0	7	4	1	4	2	2	2	2	3	1	1	2	4	C07-08
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09
Other oropharynx	0	0	0	0	0	0	0	2	1	2	0	1	0	0	0	0	0	1	0	0	C10
Nasopharynx	1	2	1	4	2	0	5	4	2	0	1	1	4	3	5	3	2	1	2	5	C11
Hypopharynx	0	1	2	1	1	2	1	2	1	0	3	1	1	0	0	0	0	0	1	0	C12-13
Pharynx unspecified	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	1	0	1	0	0	C14
Oesophagus	8	9	13	12	9	7	5	4	4	5	6	10	6	8	5	4	9	2	3	5	C15
Stomach	25	26	30	26	22	20	30	20	31	33	28	18	15	24	23	25	29	31	34	22	C16
Small intestine	2	1	1	0	0	3	2	0	2	1	1	0	2	1	1	2	3	4	0	2	C17
Colon	7	6	13	3	11	10	9	13	12	15	13	20	21	23	16	23	42	28	48	43	C18
Rectum	4	6	9	0	8	7	9	11	7	6	12	11	9	12	19	16	16	24	23	23	C19-20
Anus	0	0	0	0	1	0	1	2	1	2	2	3	1	1	2	3	0	0	2	2	C21
Liver	2	12	12	16	13	11	8	8	6	9	11	4	5	16	15	10	14	17	31	25	C22
Gallbladder etc.	4	4	4	5	3	6	2	2	3	4	6	4	6	6	2	6	8	4	6	5	C23-24
Pancreas	3	3	8	5	5	7	3	3	7	8	4	1	7	4	5	8	9	15	11	10	C25
Nose, sinuses etc.	0	1	2	0	1	1	4	1	0	2	0	2	0	4	1	1	0	0	1	2	C30-31
Larynx	2	1	2	0	2	2	2	1	1	1	2	1	0	3	1	0	1	2	1	4	C32
Trachea, bronchus and lung	13	11	7	8	8	13	5	9	10	9	13	6	11	14	7	14	20	17	16	18	C33-34
Other thoracic organs	0	2	0	1	0	0	0	2	0	1	0	2	2	0	1	1	3	0	1	2	C37-38
Bone	2	8	3	7	4	2	3	5	5	4	7	2	2	1	3	8	10	12	6	0	C40-41
Melanoma of skin	2	3	1	1	4	0	1	1	2	0	1	3	2	2	2	4	1	1	0	3	C43
Other skin	12	9	11	24	20	14	7	11	10	17	14	8	16	19	24	20	20	24	20	32	C44
	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	C45
Mesothelioma			1	4			1			0		1			1	0					
Kaposi sarcoma	0	0			2	0	•	3	0		0	1	2	1			0	1	0	0	C46
Connective and soft tissue	6	10	4	5	10	4	7	2	10	6	6	5	5	2	4	3	10	6	4	11	C47,C49
Breast	51	58	57	59	73	77	75	64	95	97	101	109	121	123	139	162	157	178	173	212	C50
Vulva	1	2	0	1	1	1	1	4	3	0	3	2	0	0	1	0	2	2	0	0	C51
Vagina	0	1	2	0	3	1	2	0	2	1	4	0	2	0	0	2	4	1	4	1	C52
Cervix uteri	26	25	29	25	32	24	17	34	30	25	30	25	30	13	36	31	26	26	32	34	C53
Corpus uteri	2	1	4	1	3	6	7	8	10	7	9	10	13	13	14	24	14	17	19	24	C54
Uterus unspecified	10	8	4	3	0	6	3	2	3	1	2	3	6	2	3	6	5	5	7	7	C55
Ovary	9	17	31	31	26	23	19	17	13	25	23	24	20	16	22	23	22	30	38	34	C56
Other female genital organs	0	0	0	0	0	0	1	0	1	0	2	3	0	0	0	0	0	2	0	1	C57
Placenta	0	1	2	3	5	2	0	1	1	0	1	1	0	1	0	3	1	0	0	1	C58
Kidney	11	6	8	4	11	12	6	10	3	11	4	6	17	8	9	21	10	15	15	17	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	1	0	0	0	C66
Bladder	9	10	8	12	6	10	12	8	11	9	15	10	10	10	9	8	11	9	15	12	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	C68
Eye	5	3	4	5	2	1	2	2	2	3	1	3	1	1	2	3	2	2	1	0	C69
Brain, nervous system	10	15	18	17	13	19	9	8	21	10	13	11	14	12	20	14	7	13	18	19	C70-72
Thyroid	31	32	36	35	26	41	36	36	30	36	40	38	40	52	40	73	73	109	96	135	C73
Adrenal gland	0	5	2	1	3	3	1	3	1	0	3	0	4	1	0	4	3	3	2	3	C74
Other endocrine	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0	C75
Hodgkin disease	12	5	5	9	14	6	10	11	5	8	5	9	15	11	14	23	10	21	15	17	C81
Non-Hodgkin lymphoma	12	29	20	9 19	29	27	23	32	33	o 26	22	9 27	30	30	41	42	30	35	33	56	C82-85,C96
mmunoproliferative diseases					29 0			32 0	33 0	20		0							33 1		
	0	0	0	0		0	0				0		0	0	0	0	0	0		2	C88
Multiple myeloma	4	9	6	9	10	2	1	6	5	5	7	3	3	6	6	5	10	9	6	11	090
_ymphoid leukaemia	9	8	12	9	11	14	11	12	12	14	12	11	21	10	15	13	19	18	22	22	C91
Myeloid leukaemia	6	8	7	9	15	12	7	11	10	7	9	12	14	13	18	16	15	17	19	19	C92-94
Leukaemia unspecified	3	1	3	5	4	8	11	11	4	2	2	7	3	3	0	3	0	2	5	0	C95
Myeloproliferative disorders	1	0	2	0	0	0	0	1	0	1	0	1	1	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	2	3	0	0	0	0	0	0	0	MDS
Other and unspecified	25	35	34	25	19	18	27	21	22	25	23	28	11	14	9	19	10	16	14	15	0&U
All sites	342	403	422	414	439	430	388	421	442	444	468	461	506	492	546	658	640	729	762	872	ALL
									432	427	454		490	473					742		

### Table 12: Age – Adjusted Incidence Rates in Omani Males by year, 1996-2015

OITE	4000	1007	1000	1000	0000	0004	0000	0000	000 (	0005	0000	0007	0000	0000	0010	0044	0040	0040	004.4	0015	
SITE	1996 0.2	1997 0.5	1998 0.7	1999 0.7	2000 0.5	2001 0.4	2002	2003 0	2004 0.8	2005 0.3	2006 0.5	2007 0	2008 0.1	2009 0	2010 0.3	2011 0.4	2012 0.1	2013 0.2	2014 0	2015 0	ICD (10th) C00
Lip																					
Tongue	1.3	0.9	0.3	1.2	1.3	0.7	0.7	0.9	0.8	1	1.5	1.3	1.2	0.7	0.8	0.9	0.7	2.1	0.8	2.1	C01-02
Mouth	1.6	1.1	1.6	1	0.8	0.6	1.5	0.9	3	1.9	0.3	1.1	1.3	1.7	0.7	1.7	1.2	0.6	1.3	0.6	C03-06
Salivary glands	0.3	0.3	1.3	0	0.2	0.3	0.5	0.1	1.8	0	0	0.1	0.3	0.2	0.5	0	0.3	0.4	0.2	0.5	C07-08
Tonsil	0	0.2	0	0.2	0	0.3	0	0	0.3	0.2	0.5	0.6	0.2	0	0.2	0	0	0.1	0	0.2	C09
Other oropharynx	0	0	0	0	0.5	0	0	0.7	0.8	0.8	0.4	0	0.3	0.2	0.2	0.4	0	0.2	0.2	0.4	C10
Nasopharynx	0.9	1.7	0.8	0.4	1.5	1.3	0.3	0.4	0.7	1	0.6	0.9	1.5	1.1	0.8	0.8	0.3	0.3	1.3	1.4	C11
Hypopharynx	0.6	0.3	0.2	0.4	0.2	0.1	0.7	0.2	2.3	0	0	0	0.3	0.7	0	0	0	0	0.1	0.3	C12-13
Pharynx unspecified	0.2	0.2	0	0	0	0	0	0.3	0.3	0	0	0.3	0	0.2	0	0.2	0	0.1	0.1	0.2	C14
Oesophagus	3.7	2.9	2.6	2.6	2.4	2.6	2.8	2.1	3.7	3.5	3.2	2.6	1.3	2.1	4	2.3	1.8	1.5	2.2	1.3	C15
Stomach	11.7	14.6	13.5	13.9	13	13.4	11.9	7.8	11.9	16.2	13	10.1	8.8	13.1	7.5	13.9	11.3	8.1	9	5.7	C16
Small intestine	0.2	0.2	0.2	0.3	0.2	0.4	0.6	0	0	0.4	0	0.5	0	0.5	0.4	1.1	0.4	0.6	0.7	1.6	C17
Colon	2.7	2.8	3.5	1.5	3	2.4	3.1	3.2	4.7	5.8	5.8	5.1	4.4	4.9	6.3	6.8	7.3	6.7	6.3	7	C18
Rectum	1.5	3.4	2.5	1.8	1.1	3	1.6	3.1	1.6	4.5	3.7	3	2.4	4.8	2.1	5.5	4.1	4.4	3.1	5	C19-20
Anus	0.8	0	0.2	0.6	0.3	1.2	0.8	0.7	0.9	0.3	0.3	0.5	0.5	0.2	0.3	0.7	0.6	0.6	0.3	0.3	C21
Liver	5.9	4.1	7.8	9.5	6.1	6.8	3	5	8.4	9.8	4.6	4.7	8	4.3	4.2	6.4	5.5	4.5	8	5.9	C22
Gallbladder etc.	0	0.9	0.5	1	1.2	0.5	0.7	0.7	1.7	2.3	0.5	1.8	0.9	1	1.3	1.9	0.3	0.8	0.5	0.9	C23-24
Pancreas	2.3	2.8	1.3	1.7	2.3	3	0.5	1.4	4.1	2.3	1.9	1.2	2.3	2.4	3.4	3.7	2.7	3.7	2.2	2.7	C25
Nose, sinuses etc.	0.2	0.6	0.2	0.7	0.5	0	0	0.3	0.8	0.6	0.4	0.9	0.1	0.2	0.2	0.7	0	0	0	0.2	C30-31
Larynx	1.9	1.1	2.7	1	1.2	0.4	0.4	1.7	3.3	2.9	2.5	1.3	1.1	0.8	2.7	1.6	1.1	1.2	1	1.1	C32
Trachea, bronchus and lung	7.5	13	8.4	13.1	8.8	9.9	6.8	6.9	10.6	8.3	8.2	11.2	7.6	7.8	6.3	11.2	5	7.3	8	6.9	C33-34
Other thoracic organs	1	0.8	0.2	0.2	0.6	0.5	0.2	0.1	0.7	0.1	0.6	0.3	0.1	0.7	0	1.2	0	0.2	0.4	0.1	C37-38
Bone	0.7	1.3	1.1	0.8	0.7	0.2	0.7	0.9	1.6	0.9	0.3	0.5	0.3	1	1.4	1.8	0.7	0.7	0.8	0.6	C40-41
Melanoma of skin	0.5	0.9	0.3	0	0.2	1	0.4	0.3	1.1	0.3	0	0.3	0.5	0.8	0.6	0.7	0.4	0.7	0.2	0.3	C43
Other skin	7.7	6.9	5.8	3.1	3.4	3.8	5.4	4.1	5	5.4	5.1	5.9	5.7	6.2	5.2	4.8	3.7	4.5	3.2	3.1	C44
Mesothelioma	0	0	0.4	0.4	0.2	0.2	0	0.3	0	0	0.3	0.3	0.3	0	0	0.9	0.1	0.2	0.3	0.2	C45
Kaposi sarcoma	0.6	1.7	0.4	1.3	0.2	0.5	0.8	0.7	0	0.5	0.7	0.5	0.5	0.5	0.3	1.4	0.1	0.6	0	0.1	C46
Connective and soft tissue		2		1.5	2	1.3	0.9	1.5	2	0.8	0.6	0.3	1.2	0.5		0.9	0.7	0.9	1	1.9	C47,C49
Breast	1.4	2	1.6						2						1.4						
	0.5		0.6	0.7	0.7	1.4	0.8	1.1		1.7	1.8	0.9	0.1	1.4	2	1.3	1.4	0.8	1.8	0.9	C50
Penis	0	0.2	0	0	0	0	0	0	0	0.2	0	0	0.3	0	0.3	0	0	0	0.1	0.1	C60
Prostate	10.8	12.9	11.4	12	9	10.6	7.3	6.9	11.2	12.3	8.7	16.1	12.3	13.1	12.8	17	13.5	13.7	12.7	13.3	C61
Testis	0.6	0.5	0.5	0.5	0.2	0.7	0.9	0.7	1	0.5	0.7	0.5	0.7	0.5	0.5	0.7	0.4	0.6	0.8	0.9	C62
Other male genital organs	0	0	0	0	0	0	0	0	0.5	0	0	0	0.1	0.1	0	0	0	0	0	0.1	C63
Kidney	1.6	1.9	1.3	1.6	2.6	1.2	1.2	2.9	1.7	2.5	1.2	1.4	2	3.9	4.1	2.6	2.2	2.2	3.6	2.7	C64
Renal pelvis	0.3	0	0	0	0	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0.2	C65
Ureter	0	0	0	0	0	0.3	0	0	0	0	0.3	0	0	0	0	0	0.2	0	0	0.2	C66
Bladder	8.3	7.5	5.8	6.6	3.8	4.4	4.1	4.8	5.9	7.7	7.5	8.8	6.9	6.7	8.9	8.7	6	7.8	8.3	6.6	C67
Other urinary organs	0	0	0.2	0.3	0.1	0	0.2	0	0	0	0.6	0	0	0	0	0	0	0	0	0	C68
Eye	1.5	1	0.8	0.6	0.3	0.3	0	0.8	0.9	1.1	0.5	1.1	0.3	0.1	0	0.2	0.1	0.2	0	0.2	C69
Brain, nervous system	2.4	4	3.8	2.9	3	4.4	3.2	3.2	4.1	2.8	1.5	2.4	1.8	3.4	2.6	2.8	3.5	2.3	3.2	2.1	C70-72
Thyroid	1.9	2.2	1.3	1.7	1.1	2.8	1.6	3.2	1.6	2	0.9	1.1	2	1.7	0.6	2.4	2	2.4	3.2	2.7	C73
Adrenal gland	0	0.1	0	0.1	0.2	0.1	0	0.3	0.2	0.2	0.4	0.1	0	0.3	0.7	0.3	0.7	0.3	0.4	0.3	C74
Other endocrine	0	0.2	0	0.1	0	0.2	0	0	0.3	0	0.1	0.1	0	0.1	0	0	0	0.1	0.2	0	C75
Hodgkin disease	1.9	2.2	3.4	2.2	2.7	3	2.4	2.4	3.5	2.3	2.2	1.6	3	1.7	1.8	3.5	3	2.2	2.6	2.3	C81
Non-Hodgkin lymphoma	8.9	8.6	9.5	9	7.9	7.3	7.1	9.9	11.3	9.4	7.8	7.4	9.7	7.5	7.6	10.9	7.5	7.2	8.3	8.6	C82-85,C96
Immunoproliferative diseases	0.2	0	0.2	0	0	0	0	0	0	0	0	0	0.3	0	0	0.3	0	0	0	0.1	C88
Multiple myeloma	1.3	3.8	2	1.6	2.4	2.1	1.4	0.8	3.1	3.5	1.2	2.9	2.5	2.2	1.8	1.8	2.2	2.1	1.5	1.4	C90
Lymphoid leukaemia	1.6	2.4	1.9	2.5	2.5	2.6	2.4	3.3	3.8	2.3	2.5	1.7	2.5	3.6	2.6	5.3	1.7	1.6	3.3	2.3	C91
Myeloid leukaemia	1	2	2.9	1.9	2.9	1.8	1.9	3.1	1.9	2.6	3.5	3.8	3.3	1.9	2	4.3	2.4	2	2.4	2.7	C92-94
Leukaemia unspecified	1.3	0.5	0.6	0.8	0.6	1.2	1.2	1.1	0.6	0.4	0.1	0.4	0.2	0.3	0.2	0.3	0.2	0.7	0.1	0	C95
Myeloproliferative disorders	0	0.5	0.3	0.0	0.0	0	0.2	0.1	0.0	0.4	0.2	0.4	0.2	0.3	0.2	0.1	0.2	0.7	0.1	0.1	MPD
	0	0	0.5	0.2	0	0	0.2	0.1	0	0.1	0.2	0.7	0.3	0.5	0.5	0.1	0	0	0.1	0.1	MDS
Myelodysplastic syndromes																					
Other and unspecified	6.3	7.4	7.2	5.2	6.8	5.3	5.3	4.1	9	4.6	5.8	5.4	4.1	5	3.1	5.9	4	2.7	1.1	2.2	0&U
All sites	106	124	112	109	99.4	105	85.7	92.8	135	127	103	113	104	111	104	141	99.3	100	105	101	ALL
All sites but C44	98.4	117	106	106	96	101	80.3	88.7	130	121	98	107	97.9	104	98.5	136	95.6	95.7	102	97.7	ALLbC44

### Table 13: Age – Adjusted Incidence Rates in Omani Females by year, 1996-2015

Lip     0       Tongue     1       Mouth     0       Salivary glands     0       Tonsil     0       Other oropharynx     0       Nasopharynx     0       Nasopharynx     0       Pharynx unspecified     0       Obsophagus     2       Stomach     7       Small intestine     0       Colon     2       Recturn     1       Anus     0       Galibladder etc.     1       Pancreas     0       Nose, sinuses etc.     0       Bone     0       Other thoracic organs     0       Bone     0       Colnonctive and soft tissue     1       Pancreas     0       Corpresion     0       Bone     0       Corpresion     1       Pracetas     0       Connective and soft tissue     1       Breast     12       Vulva     0       Corpus uteri     1       Other female genital organs     0       Placenta     0       Vidrey     2       Quary     1	.7 .4 .3 .3 .2 .2 .5 .1 .1 .1 .6 .6 .3 .8 .5 .1 .1 .4 .4 .4 .4 .4	1997         0         0.2         2         0.1         0         0.1         0         0.1         0         0.1         0         0.4         0.4         0.3         1.6         1.6         0.3         3.6         1.2         0.8         0.2         2.8         0.4         1.1         1.2         2.6         0         0	1998         0.4         0         0.2         0.5         0         0.2         0.4         0         0.2         0.4         0         0.4         0         4.4         8.2         0.3         3.1         2.1         0         3.2         1.1         2.4         0.5         0.4         1.6         0         0.2         0.2         2.9	1999 0 0,9 1 0,4 0 0 0 0 8,8 0,4 0 0 3,3 7 0 1 0 0 1 0 0 4,1 1,2 0 0 0 2,1 0,0 5 0 1 0,0 0 0 1,0 0 0 0 0 0 0 0 0 0 0 0 0	2000 0 0.5 0.4 0.2 0 0 0.2 0.2 0.2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.8 1.3 0.3 0.4 2 2	2001 0 0.4 0.3 0 0 0 0.4 0.3 0 0 0.4 0.3 1.7 2.4 1.5 0 2.5 1.4 1.8 0.1 1.5	2002 0 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2003 0.2 0.4 0.7 1.2 0 0.6 0.7 0.5 0 0.5 0 4.3 0 2.4 2.6 0.5 1.9 0.5 0.5 0.5	2004 0.2 0.3 0.6 0.8 0.3 0.1 0.5 0 2.1 10.6 0.6 4 2 0.4 2 0.4 1.9	2005 0 0.2 0.6 0.4 0 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2006 0.3 0.4 0.3 0.7 0 0 0.2 0.7 0 2 7.1 0.3 2.7 0.5 2.5	2007 0.4 0.5 1.3 0.4 0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6 1.2	2008 0.5 0.3 0.8 0.2 0 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3 1.7	2009 0 0.3 1.5 0.3 0 0 0 0 2.4 6 0.3 4.8 2.6 0.3	2010 0 0.8 0.9 0.2 0 0 0 0 0 0 0 0 1.1 5.5 0.2 2.8 4.1 0.6	2011 0 1 0.7 0.6 0 0 0 0 0 0 0 0 0 2 2 1.2 5.1 0.5 4.6 3.2	2012 0.3 0.5 0.5 0.1 0 0 0.3 0 0 1.6 4.8 0.5 7.2 2.5	2013 0 0.2 0.9 0.2 0 0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7 0	2014 0 1 1.1 0.2 0 0 0 0.3 0.1 0 0.5 5.5 0 7 3.4 0.3	2015 0.2 0.7 0.4 0.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ICD (10th) C00 C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 C15 C14 C15 C16 C17 C18 C19-20 C21
Tongue         1.           Mouth         0.           Salivary glands         0           Tonsil         0           Other oropharynx         0           Nasopharynx         0.           Hypopharynx         0           Pharynx unspecified         0           Oosophagus         2.           Stomach         7.           Small intestine         0.           Colon         2.           Recturm         1.           Anus         0           Gallbladder etc.         1.           Pancreas         0.           Cher thoracic organs         0           Bone         0.           Other thoracic organs         0           Cother skin         3.           Mesothelioma         0           Connective and soft tissue         1           Breast         13           Vulva         0.           Corpus uteri         1.           Uterus unspecified         2.           Ovary         1.           Other female genital organs         0           Placenta         0           Placenta         1. </td <td>.7 .4 .3 .3 .2 .2 .5 .1 .1 .1 .6 .6 .3 .8 .5 .1 .1 .4 .4 .4 .4</td> <td>0.2 2 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td>0 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td>0.9 1 0.4 0 0 0.8 0.4 0 3.3 7 0 1 0 1 0 1 1 4 1 2 0 0 2.1 0.1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td>0.5 0.4 0 0 0 0 2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.3 0.3 0.3</td> <td>0 0.4 0.3 0 0 0 0.4 0.3 1.7 2.4 1.5 0 2.5 1.4 1.8 0.1</td> <td>0.1 0.1 0 0 0.6 0.2 0 0.5 0.5 2.1 2.2 0.1 1.7 0.3 0.7</td> <td>0.4 0.7 1.2 0 0.6 0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5</td> <td>0.3 0.6 0.8 0 0.3 0.1 0.5 0 2.1 10.6 0.6 4 2 0.4 1.9</td> <td>0.2 0.6 0.4 0 0.7 0 0 0 1.9 10.1 0.4 3.5 1.2 0.7</td> <td>0.4 0.3 0.7 0 0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5</td> <td>0.5 1.3 0.4 0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6</td> <td>0.3 0.8 0.2 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3</td> <td>0.3 1.5 0.3 0 0 0.6 0 2.4 6 0.3 4.8 2.6</td> <td>0.8 0.9 0.2 0 0 0.4 0 0 1.1 5.5 0.2 2.8 4.1</td> <td>1 0.7 0.6 0 0 0.6 0.2 1.2 5.1 0.5 4.6 3.2</td> <td>0.5 0.5 0.1 0 0 0.3 0 0 1.6 4.8 0.5 7.2</td> <td>0.2 0.9 0.2 0 0.1 0.1 0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7</td> <td>1 1.1 0.2 0 0 0.3 0.1 0 0.5 5.5 0 7 3.4</td> <td>0.7 0.4 0.4 0 0 0.6 0 0 0.6 2.9 0.2 6.2 3</td> <td>C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 C15 C16 C15 C16 C17 C18 C19-20 C21</td>	.7 .4 .3 .3 .2 .2 .5 .1 .1 .1 .6 .6 .3 .8 .5 .1 .1 .4 .4 .4 .4	0.2 2 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.9 1 0.4 0 0 0.8 0.4 0 3.3 7 0 1 0 1 0 1 1 4 1 2 0 0 2.1 0.1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	0.5 0.4 0 0 0 0 2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.3 0.3 0.3	0 0.4 0.3 0 0 0 0.4 0.3 1.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0.1 0.1 0 0 0.6 0.2 0 0.5 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.4 0.7 1.2 0 0.6 0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.3 0.6 0.8 0 0.3 0.1 0.5 0 2.1 10.6 0.6 4 2 0.4 1.9	0.2 0.6 0.4 0 0.7 0 0 0 1.9 10.1 0.4 3.5 1.2 0.7	0.4 0.3 0.7 0 0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	0.5 1.3 0.4 0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0.3 0.8 0.2 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0.3 1.5 0.3 0 0 0.6 0 2.4 6 0.3 4.8 2.6	0.8 0.9 0.2 0 0 0.4 0 0 1.1 5.5 0.2 2.8 4.1	1 0.7 0.6 0 0 0.6 0.2 1.2 5.1 0.5 4.6 3.2	0.5 0.5 0.1 0 0 0.3 0 0 1.6 4.8 0.5 7.2	0.2 0.9 0.2 0 0.1 0.1 0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7	1 1.1 0.2 0 0 0.3 0.1 0 0.5 5.5 0 7 3.4	0.7 0.4 0.4 0 0 0.6 0 0 0.6 2.9 0.2 6.2 3	C01-02 C03-06 C07-08 C09 C10 C11 C12-13 C14 C15 C16 C15 C16 C17 C18 C19-20 C21
Mouth     0.       Salivary glands     0       Tonsil     0       Other oropharynx     0       Nasopharynx     0       Phaynx unspecified     0       Obesophagus     2.       Stomach     7.       Small intestine     0.       Colon     2.       Stomach     7.       Small intestine     0.       Colon     2.       Recturm     1.       Anus     0       Liver     0.       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Larynx     0.       Other thoracic organs     0       Bone     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Vulva     0.       Vulva     0.       Vulva     0.       Corpus uteri     6.       Coryus viteri     6.       Coryus viteri     0.       Placenta     0       Rideny lepvisi     0	.4 .3 .2 .2 .5 .1 .1 .1 .6 .3 .8 .8 .5 .1 .1 .4 .4 .4 .4	2 0.1 0 0 0 4 0 4 0 3 3 7.1 0 3 1.6 1.6 0 3.6 1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	0.2 0.5 0 0.2 0.4 0.4 0.4 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 0.5 0.4 0.5 0.2 0.2	1 0.4 0 0.8 0.4 0 3.3 7 0 1 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0.4 02 0 0 0 2 0 2 1 5.7 0 2.4 2 0 2 4 2 0 2 3.1 0 3 1 3 0 3 0 3 0 3 0 3 0 3 0 0 2 0 0 0 0 0 0	0.4 0.3 0 0 0 0 0.4 0.3 1.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0.1 0 0 0.6 0.2 0 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.7 1.2 0 0.6 0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.6 0.8 0 0.3 0.1 0.5 0 2.1 10.6 4 2 2 0.4 2 0.4 1.9	0.6 0.4 0 0.7 0 0 0 1.9 10.1 0.4 3.5 1.2 0.7	0.3 0.7 0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	1.3 0.4 0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0.8 0.2 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	1.5 0.3 0 0.6 0 0 2.4 6 0.3 4.8 2.6	0.9 0.2 0 0.4 0 1.1 5.5 0.2 2.8 4.1	0.7 0.6 0 0.6 0 0.2 1.2 5.1 0.5 4.6 3.2	0.5 0.1 0 0.3 0 0 1.6 4.8 0.5 7.2	0.9 0.2 0 0.1 0.1 0 0.1 0.4 4.5 0.5 4.1 3.7	1.1 0.2 0 0.3 0.1 0.5 5.5 0 7 3.4	0.4 0.4 0 0 0.6 0 0 0 0.6 2.9 0.2 6.2 3	C03-06 C07-08 C09 C10 C11 C12-13 C14 C15 C16 C15 C16 C17 C18 C19-20 C21
Salivary glands     0       Tonsil     0       Other oropharynx     0       Nasopharynx     0       Hypopharynx     0       Pharynx unspecified     0       Ocsophagus     2       Stomach     7       Stmali intestine     0       Colon     2       Rectum     1       Anus     0       Liver     0       Galibladder etc.     1       Pancreas     0       Other thoracic organs     0       Bone     0       Other skin     3       Mesothelioma     0       Connective and soft tissue     1       Breast     1       Vulva     0       Corpus uteri     6       Corpus uteri     6       Corpus uteri     2       Ovary     1       Differ female genital organs     0       Placenta     0       Kidney     2		0.1 0 0.4 0.4 0 3 7.1 0.3 7.1 0.3 1.6 1.6 0 3.6 1.2 0.2 2.8 0.2 2.8 0.4 1.1 1.2 2.6	0.5 0 0 0.2 0.4 0 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0.4 0 0 0.8 0.4 0 3.3 7 0 1 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0.2 0 0 0.2 0.2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.3 0.3 0.3 0.3	0.3 0 0 0 0.4 0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0 0 0 0.2 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	1.2 0 0.6 0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.8 0 0.3 0.1 0.5 2.1 10.6 4 2 2 0.4 1.9	0.4 0 0.7 0 0 1.9 10.1 0.4 3.5 1.2 0.7	0.7 0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	0.4 0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0.2 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0.3 0 0.6 0 2.4 6 0.3 4.8 2.6	0.2 0 0.4 0 1.1 5.5 0.2 2.8 4.1	0.6 0 0.6 0.2 1.2 5.1 0.5 4.6 3.2	0.1 0 0.3 0 0 1.6 4.8 0.5 7.2	0.2 0 0.1 0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7	0.2 0 0.3 0.1 0 0.5 5.5 0 7 3.4	0.4 0 0.6 0 0 0.6 2.9 0.2 6.2 3	C07-08 C09 C10 C12-13 C14 C15 C16 C16 C17 C18 C19-20 C21
Tonsil     0       Other oropharynx     0       Nasopharynx     0       Hypopharynx     0       Pharynx unspecified     0       Oesophagus     2       Stomach     7       Small intestine     0       Colon     2       Rectum     1       Anus     0       Liver     0       Galtbladder etc.     1       Pancreas     0       Nose, sinuses etc.     0       Larynx     0       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Yulva     0       Corpus uteri     6.       Corpus uteri     6.       Corpus uteri     0       Uter temale genital organs     0       Placenta     0       Vianja Lievis     0		0 0.4 0.4 0 3 7.1 0.3 1.6 0 3.6 0 3.6 0 2.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0 0	0 0 0.2 0.4 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 0.5 0.4 0.5 0.2 0.2	0 0.8 0.4 0 3.3 7 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0 0 0.2 0.2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.3 0.3 0.3 0.4	0 0 0 0.4 0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0 0.6 0.2 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0 0.6 0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0 0.3 0.1 0.5 0 2.1 10.6 4 2 2 0.4 1.9	0 0.7 0 0 1.9 10.1 0.4 3.5 1.2 0.7	0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	0 0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0 0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0 0.6 0 2.4 6 0.3 4.8 2.6	0 0.4 0 1.1 5.5 2.8 4.1	0 0.6 0.2 1.2 5.1 0.5 4.6 3.2	0 0.3 0 1.6 4.8 0.5 7.2	0 0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7	0 0.3 0.1 0.5 5.5 0 7 3.4	0 0.6 0 0.6 2.9 0.2 6.2 3	C09 C10 C11 C12-13 C14 C15 C15 C16 C17 C18 C19-20 C21
Other oropharynx     0       Nasopharynx     0       Hypopharynx     0       Pharynx unspecified     0       Oesophagus     2       Stornach     7       Small intestine     0       Colon     2       Rectum     1       Anus     0       Galtbladder etc.     1       Pancreas     0       Larynx     0       Larynx     0       Other thoracic organs     0       Bone     0       Other skin     3       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Yulva     0       Corpus uteri     6       Corpus uteri     6       Corpus uteri     0       Uter female genital organs     0       Placenta     0       Ridney     2       Renal pelvis     0	.2 .2 .5 .1 .1 .6 .3 .8 .5 .1 .1 .4 .4 .4	0 0.4 0.4 0 3 7.1 0.3 1.6 0 3.6 0.2 0.2 2.8 0.2 2.8 0.4 1.1 1.2 2.6 0 0	0 0.2 0.4 0 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0 0.8 0.4 0 3.3 7 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0 0.2 0.2 2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	0 0.4 0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0 0.6 0.2 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.6 0.7 0.5 0 9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.3 0.1 0.5 0 2.1 10.6 0.6 4 2 0.4 1.9	0.7 0 0 1.9 10.1 0.4 3.5 1.2 0.7	0 0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	0.3 0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0 1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0 0.6 0 2.4 6 0.3 4.8 2.6	0 0.4 0 1.1 5.5 0.2 2.8 4.1	0 0.6 0.2 1.2 5.1 0.5 4.6 3.2	0 0.3 0 1.6 4.8 0.5 7.2	0.1 0.1 0.1 0.4 4.5 0.5 4.1 3.7	0 0.3 0.1 0 0.5 5.5 0 7 3.4	0 0.6 0 0.6 2.9 0.2 6.2 3	C10 C11 C12-13 C14 C15 C15 C16 C17 C18 C19-20 C21
Nasopharynx     0.       Hypopharynx     0       Pharynx unspecified     0       Desophagus     2.       Stomach     7.       Small intestine     0.       Colon     2.       Rectum     1.       Anus     0       Gallbladder etc.     1.       Pancreas     0.       Colon, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Yulva     0.       Corpus uteri     6.       Corpus uteri     6.       Corpus uteri     6.       Ovary     1.       Placenta     0       Kidney     2.       Renal pelvis     0	.3 .2 .2 .5 .1 .1 .6 .3 .8 .8 .5 .1 .4 .4 .4 .4	0.4 0.4 0 3 7.1 0.3 1.6 0 3.6 1.2 0.8 0.2 2.8 0.4 1.1 1.2 2.6 0 0 0 0 0 0 0 0 0 0 0 0 0	0.2 0.4 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0.8 0.4 0 3.3 7 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0.2 0.2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.3 0.4	0 0.4 0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0.6 0.2 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.7 0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.1 0.5 2.1 10.6 4 2 0.4 1.9	0 0 1.9 10.1 0.4 3.5 1.2 0.7	0.2 0.7 0 2 7.1 0.3 3 2.7 0.5	0.2 0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	1 0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0.6 0 2.4 6 0.3 4.8 2.6	0.4 0 1.1 5.5 0.2 2.8 4.1	0.6 0 0.2 1.2 5.1 0.5 4.6 3.2	0.3 0 1.6 4.8 0.5 7.2	0.1 0 0.1 0.4 4.5 0.5 4.1 3.7	0.3 0.1 0.5 5.5 0 7 3.4	0.6 0 0.6 2.9 0.2 6.2 3	C11 C12-13 C14 C15 C16 C17 C18 C19-20 C21
Hypopharynx     0       Pharynx unspecified     0       Desophagus     2.       Stomach     7.       Small intestine     0.       Colon     2.       Recturn     1.       Anus     0       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Vulva     0.       Corpus uteri     6.       Corpus uteri     2.       Ovary     1.       Placenta     0       Kidney     2.	.2 .2 .5 .1 .1 .1 .5 .1 .4 .4 .4 .4	0.4 0 3 7.1 0.3 1.6 0 3.6 1.2 0.8 0.2 2.8 0.4 1.1 1.2 2.6 0 0 0 0 0 0 0 0 0 0 0 0 0	0.4 0 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0.4 0 3.3 7 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0.2 0 2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	0.4 0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0.2 0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.5 0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0.5 0 2.1 10.6 4 2 0.4 1.9	0 0 1.9 10.1 0.4 3.5 1.2 0.7	0.7 0 2 7.1 0.3 3 2.7 0.5	0.3 0.1 3.1 5.1 0 4.6 2.5 0.6	0.3 0.3 1.7 4.1 0.6 4.3 1.9 0.3	0 0 2.4 6 0.3 4.8 2.6	0 0 1.1 5.5 0.2 2.8 4.1	0 0.2 1.2 5.1 0.5 4.6 3.2	0 0 1.6 4.8 0.5 7.2	0 0.1 0.4 4.5 0.5 4.1 3.7	0.1 0 0.5 5.5 0 7 3.4	0 0.6 2.9 0.2 6.2 3	C12-13 C14 C15 C16 C17 C18 C19-20 C21
Pharynx unspecified 0 Oesophagus 2. Stomach 7. Small intestine 0. Colon 2. Recturn 1. Anus 0 Colon 2. Recturn 1. Anus 0 Calibladder etc. 1. Pancreas 0. Nose, sinuses etc. 0. Larynx 0. Trachea, bronchus and lung 4. Other thoracic organs 0 Bone 0. Melanoma of skin 0. Other skin 3. Mesothelioma 0. Melanoma of skin 0. Other skin 3. Mesothelioma 0 Connective and soft tissue 11 Breast 12 Vulva 0. Connective and soft tissue 11 Breast 12 Vulva 0. Connective and soft tissue 12 Breast 12 Vulva 0. Vagina 00 Cervix uteri 6. Corpus uteri 0. Uterus unspecified 2. Ovary 1. Other female genital organs 0 Placenta 0 Kidney 2. Renal pelvis 0	.2 .2 .5 .1 .1 .1 .6 .3 .8 .5 .1 .4 .4 .4 .4	0 3 7.1 0.3 1.6 0 3.6 1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0 0	0 4.4 8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0 3.3 7 0 1 0 0 4.1 1.4 1.2 0 0 0 2.1 0.1	0 2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	0.3 1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0 1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0 0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	0 2.1 10.6 4 2 0.4 1.9	0 1.9 10.1 0.4 3.5 1.2 0.7	0 2 7.1 0.3 3 2.7 0.5	0.1 3.1 5.1 0 4.6 2.5 0.6	0.3 1.7 4.1 0.6 4.3 1.9 0.3	0 2.4 6 0.3 4.8 2.6	0 1.1 5.5 0.2 2.8 4.1	0.2 1.2 5.1 0.5 4.6 3.2	0 1.6 4.8 0.5 7.2	0.1 0.4 4.5 0.5 4.1 3.7	0 0.5 5.5 0 7 3.4	0 0.6 2.9 0.2 6.2 3	C14 C15 C16 C17 C18 C19-20 C21
Desophagus     2.       Stomach     7.       Stmal intestine     0.       Colon     2.       Rectum     1.       Anus     0.       Liver     0.       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0.       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0.       Bone     0.       Melanorna of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Vagina     0.       Corpus uteri     6.       Corpus uteri     0.       Uter female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	.2 .5 .1 .1 .6 .3 .8 .8 .5 .1 .1 .4 .4 .4	3 7.1 0.3 1.6 1.6 0 3.6 1.2 0.8 0.2 2.8 0.2 2.8 0.4 1.1 1.2 2.6 0	<ul> <li>4.4</li> <li>8.2</li> <li>0.3</li> <li>3.1</li> <li>2.1</li> <li>0</li> <li>3.2</li> <li>1.1</li> <li>2.4</li> <li>0.5</li> <li>0.4</li> <li>1.6</li> <li>0</li> <li>0.2</li> <li>0.2</li> </ul>	3.3 7 0 1 0 4.1 1.4 1.2 0 0 2.1 0.1	2.1 5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	1.7 4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	1.1 6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	0.9 4.3 0 2.4 2.6 0.5 1.9 0.5	2.1 10.6 4 2 0.4 1.9	1.9 10.1 0.4 3.5 1.2 0.7	2 7.1 0.3 3 2.7 0.5	3.1 5.1 0 4.6 2.5 0.6	1.7 4.1 0.6 4.3 1.9 0.3	2.4 6 0.3 4.8 2.6	1.1 5.5 0.2 2.8 4.1	1.2 5.1 0.5 4.6 3.2	1.6 4.8 0.5 7.2	0.4 4.5 0.5 4.1 3.7	0.5 5.5 0 7 3.4	0.6 2.9 0.2 6.2 3	C15 C16 C17 C18 C19-20 C21
Stomach     7.       Small intestine     0.       Colon     2.       Rectum     1.       Anus     0       Liver     0.       Galtbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Laynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Corpus uteri     0.       Other female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	.2 .5 .1 .1 .6 .6 .3 .8 .8 .5 .1 .4 .4 .4	7.1 0.3 1.6 0 3.6 1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	8.2 0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2	7 0 1 0 4.1 1.4 1.2 0 0 2.1 0.1	5.7 0 2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	4.4 0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	6.8 0.5 2.1 2.2 0.1 1.7 0.3 0.7	4.3 0 2.4 2.6 0.5 1.9 0.5	10.6 0.6 4 2 0.4 1.9	10.1 0.4 3.5 1.2 0.7	7.1 0.3 3 2.7 0.5	5.1 0 4.6 2.5 0.6	4.1 0.6 4.3 1.9 0.3	6 0.3 4.8 2.6	5.5 0.2 2.8 4.1	5.1 0.5 4.6 3.2	4.8 0.5 7.2	4.5 0.5 4.1 3.7	5.5 0 7 3.4	2.9 0.2 6.2 3	C16 C17 C18 C19-20 C21
Small intestine     0.       Colon     2.       Recturn     1.       Anus     0       Liver     0.       Galibladder etc.     1.       Pancreas     0.       System     0.       Varynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Other skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Vulva     0.       Other skin     2.       Orunective and soft tissue     1       Breast     13       Vulva     0.       Vulva     0.       Vulva     0.       Other female genital organs     0       Placenta     0       Ridney     2.       Renal pelvis     0	.5 .1 .6 .3 .8 .5 .1 .4 .4 .4	0.3 1.6 1.6 0 3.6 1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	0.3 3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0 0.2 0.2	0 1 0 4.1 1.4 1.2 0 0 2.1 0.1	0 2.4 2 0.2 3.1 0.8 1.3 0.8 0.3 0.4	0.7 2.4 1.5 0 2.5 1.4 1.8 0.1	0.5 2.1 2.2 0.1 1.7 0.3 0.7	0 2.4 2.6 0.5 1.9 0.5	0.6 4 2 0.4 1.9	0.4 3.5 1.2 0.7	0.3 3 2.7 0.5	0 4.6 2.5 0.6	0.6 4.3 1.9 0.3	0.3 4.8 2.6	0.2 2.8 4.1	0.5 4.6 3.2	0.5 7.2	0.5 4.1 3.7	0 7 3.4	0.2 6.2 3	C17 C18 C19-20 C21
Colon     2.       Rectum     1.       Anus     0       Liver     0.       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Laynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Yulva     0.       Corpus uteri     6.       Corpus uteri     6.       Corpus uteri     0.       Uther female genital organs     0       Placenta     0       Kidney     2.	.1 .1 .6 .3 .3 .8 .8 .5 .1 .1 .4 .4 .4	1.6 1.6 0 3.6 1.2 0.8 0.2 2.8 0.4 1.1 1.2 2.6 0 0	3.1 2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	1 0 4.1 1.4 1.2 0 0 2.1 0.1	2.4 2 0.2 3.1 0.8 1.3 0.3 0.4	2.4 1.5 0 2.5 1.4 1.8 0.1	2.1 2.2 0.1 1.7 0.3 0.7	2.4 2.6 0.5 1.9 0.5	4 2 0.4 1.9	3.5 1.2 0.7	3 2.7 0.5	4.6 2.5 0.6	4.3 1.9 0.3	4.8 2.6	2.8 4.1	4.6 3.2	7.2	4.1 3.7	7 3.4	6.2 3	C18 C19-20 C21
Rectum       1.         Anus       0         Liver       0.         Galtbladder etc.       1.         Pancreas       0.         Nose, sinuses etc.       0         Larynx       0.         Trachea, bronchus and lung       4.         Other thoracic organs       0         Bone       0.         Melanoma of skin       0.         Other skin       3.         Mesothelioma       0         Connective and soft tissue       1         Breast       12         Vulva       0.         Corpus uteri       6.         Corpus uteri       0.         Uter female genital organs       0         Kidney       2.         Renal pelvis       0	.1 .6 .3 .3 .8 .8 .5 .1 .1 .4 .4 .4	1.6 0 3.6 1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	2.1 0 3.2 1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	0 0 4.1 1.4 1.2 0 0 2.1 0.1	2 0.2 3.1 0.8 1.3 0.3 0.4	1.5 0 2.5 1.4 1.8 0.1	2.2 0.1 1.7 0.3 0.7	2.6 0.5 1.9 0.5	2 0.4 1.9	1.2 0.7	2.7 0.5	2.5 0.6	1.9 0.3	2.6	4.1	3.2		3.7	3.4	3	C19-20 C21
Anus     0       Liver     0.       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Corpus uteri     6.       Corpus uteri     0.       Uter sunspecified     2.       Ovary     1.       Other female genital organs     0       Kidney     2.       Renal pelvis     0		0 3.6 1.2 0.8 0.2 2.8 0.4 1.1 1.2 2.6 0	0 3.2 1.1 2.4 0.5 0.4 1.6 0 0 0.2 0.2	0 4.1 1.4 1.2 0 0 2.1 0.1	0.2 3.1 0.8 1.3 0.3 0.4	0 2.5 1.4 1.8 0.1	0.1 1.7 0.3 0.7	0.5 1.9 0.5	0.4 1.9	0.7	0.5	0.6	0.3				2.5				C21
Liver     0.       Gallbladder etc.     1.       Pancreas     0.       Nose, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     12       Vulva     0.       Caryku uteri     6.       Corpus uteri     0.       Uter female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0		3.6 1.2 0.8 0.2 2.8 0.4 1.1 1.2 2.6 0	<ol> <li>3.2</li> <li>1.1</li> <li>2.4</li> <li>0.5</li> <li>0.4</li> <li>1.6</li> <li>0</li> <li>0.2</li> <li>0.2</li> </ol>	4.1 1.4 1.2 0 0 2.1 0.1	3.1 0.8 1.3 0.3 0.4	2.5 1.4 1.8 0.1	1.7 0.3 0.7	1.9 0.5	1.9					0.3	0.6				0.3	0.2	
Gallbladder etc.       1.         Pancreas       0.         Nose, sinuses etc.       0         Larynx       0.         Trachea, bronchus and lung       4.         Other thoracic organs       0         Bone       0.         Melanoma of skin       0.         Other skin       3.         Mesothelioma       0         Connective and soft tissue       1         Breast       12         Vulva       0.         Vorgina       0         Corpus uteri       6.         Covary       1.         Other female genital organs       0         Placenta       0         Kidney       2.         Renal pelvis       0	.3 .5 .1 .4 .4	1.2 0.8 0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	1.1 2.4 0.5 0.4 1.6 0 0.2 0.2	1.4 1.2 0 2.1 0.1	0.8 1.3 0.3 0.4	1.4 1.8 0.1	0.3 0.7	0.5		2.2	2.5	1.2	17			0.6	0	0			
Pancreas     0.       Nose, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Corpus uteri     6.       Corpus uteri     0.       Utter female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	.5 .1 .4 .4	0.8 0.2 2.8 0.4 1.1 1.2 2.6 0	2.4 0.5 0.4 1.6 0 0.2 0.2	1.2 0 2.1 0.1	1.3 0.3 0.4	1.8 0.1	0.7		1.2					3.8	3.6	2	2.2	2.7	4.8	3.7	C22
Nose, sinuses etc.     0       Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Corpus uteri     6.       Corya y     1.       Other female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	.5 .1 .4 .4 .4	0.2 0.2 2.8 0.4 1.1 1.2 2.6 0	0.5 0.4 1.6 0 0.2 0.2	0 0 2.1 0.1	0.3 0.4	0.1		0.8		1.1	1.8	1.3	1.5	1.4	0.6	1.1	1.3	0.7	1	0.7	C23-24
Larynx     0.       Trachea, bronchus and lung     4.       Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Cervix uteri     6.       Corles usrpecified     2.       Ovary     1.       Other female genital organs     0       Ridney     2.       Renal pelvis     0	.5 .1 .4 .4	0.2 2.8 0.4 1.1 1.2 2.6 0	0.4 1.6 0 0.2 0.2	0 2.1 0.1	0.4		0.0		3	2	1	0.3	1.6	1	1.3	1.9	1.5	2.6	1.8	1.5	C25
Trachea, bronchus and lung 4. Other thoracic organs 0 Bone 0. Melanoma of skin 0. Other skin 3. Mesothelioma 0 Kaposi sarcoma 0 Connective and soft tissue 1 Breast 15 Vulva 0. Vagina 0 Cervix uteri 6. Corpus uteri 0. Uterus unspecified 2. Ovary 1. Other female genital organs 0 Placenta 0 Kidney 2. Renal pelvis 0	.1	2.8 0.4 1.1 1.2 2.6 0	1.6 0 0.2 0.2	2.1 0.1		0.5	0.8	0.3	0	0.4	0	0.3	0	1.1	0.3	0.2	0	0	0.1	0.3	C30-31
Other thoracic organs     0       Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Kaposi sarcoma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Vagina     0       Corpus uteri     6.       Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Kidney     2.       Renal pelvis     0	.4	0.4 1.1 1.2 2.6 0	0 0.2 0.2	0.1	2		0.4	0.3	0.2	0.2	0.8	0.3	0	0.8	0.1	0	0.2	0.4	0.2	0.5	C32
Bone     0.       Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Kaposi sarcoma     0       Connective and soft tissue     1       Breast     13       Vulva     0.       Vulva     0.       Corpus uteri     6.       Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Ridney     2.       Renal pelvis     0	.4	1.1 1.2 2.6 0	0.2 0.2			3.2	1	2.2	3.5	2.4	3.6	1.6	3	3.4	1.8	3.6	3.6	2.7	2.5	2.7	C33-34
Melanoma of skin     0.       Other skin     3.       Mesothelioma     0       Kaposi sarcoma     0       Connective and soft tissue     1       Breast     1       Breast     1       Vulva     0.       Vulva     0.       Corpus uteri     6.       Corpus uteri     0.       Utterus unspecified     2.       Ovary     1.       Other female genital organs     0       Placenta     0.       Kidney     2.       Renal pelvis     0.	.4	1.2 2.6 0	0.2	0.0	0	0	0	0.3	0	0.1	0	0.4	0.5	0	0.1	0.1	0.4	0	0.1	0.1	C37-38
Other skin     3.       Mesothelioma     0       Kaposi sarcoma     0       Connective and soft tissue     1       Breast     1       Breast     1       Vulva     0.       Vagina     0       Cervix uteri     6.       Corpus uteri     6.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Placenta     0       Kidneny lepvis     0	.4	2.6 0		0.6	0.4	0.4	0.2	0.3	0.8	0.7	0.8	0.1	0.1	0.1	0.3	0.9	1	1.3	0.5	0	C40-41
Mesothelioma       0         Kaposi sarcoma       0         Connective and soft tissue       1         Breast       13         Vulva       0         Vagina       0         Corryix uteri       6./         Corpus uteri       0.         Utterus unspecified       2.         Ovary       1.         Other fernale genital organs       0         Placenta       0         Kidney       2.         Renal pelvis       0		0	2.9	0.1	0.9	0	0.1	0.2	0.5	0	0.1	0.5	0.5	0.4	0.4	0.6	0.2	0.2	0	0.5	C43
Kaposi sarcoma     0       Connective and soft tissue     1       Breast     13       Vulva     0       Vagina     0       Cervix uteri     6.       Corpus uteri     0.       Utterus unspecified     2.       Ovary     1.       Other fermale genital organs     0       Placenta     0       Kidney     2.		-	2.0	5.4	4.8	3.3	1.5	2.5	4	4	4.1	2.1	5	4.8	5.2	3.9	3.4	3.9	3	4.3	C44
Connective and soft tissue 1 Breast 1 Stulva 0 Vagina 0 Cervix uteri 6 Corpus uteri 0 Uterus unspecified 2 Ovary 1 Other female genital organs 0 Placenta 0 Kidney 2 Renal pelvis 0		0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2	C45
Breast     12       Vulva     0.       Vagina     0       Cervix uteri     6.       Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0			0.2	0.9	0.4	0	0.2	0.6	0	0	0	0.2	0.7	0.4	0.3	0	0	0.2	0	0	C46
Vulva     0.       Vagina     0       Cervix uteri     6.       Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	3.6	1.9	0.3	1.1	1.5	0.6	1	0.3	1.9	0.7	0.8	0.7	0.7	0.2	0.3	0.2	1.2	0.7	0.5	1.1	C47,C49
Vagina 0 Cervix uteri 6. Corpus uteri 0. Uterus unspecified 2. Ovary 1. Other female genital organs 0 Placenta 0 Kidney 2. Renal pelvis 0		13.8	13.2	13.9	15.4	16	15	13.6	25.6	22.3	23.5	23.2	25	23.3	25	28.1	24.2	25.1	22.2	26.9	C50
Cervix uteri     6.       Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other fernale genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0	.2	0.7	0	0.4	0.3	0.3	0.2	0.8	1	0	1	0.3	0	0	0.2	0	0.3	0.3	0	0	C51
Corpus uteri     0.       Uterus unspecified     2.       Ovary     1.       Other female genital organs     0       Placenta     0       Kidney     2.       Renal pelvis     0		0.4	0.6	0	0.6	0.2	0.5	0	0.4	0.1	1.5	0	0.8	0	0	0.1	0.7	0.1	0.7	0.2	C52
Uterus unspecified 2. Ovary 1. Other female genital organs 0 Placenta 0 Klidney 2. Renal pelvis 0	.6	6.6	7.2	6.3	7.3	5.7	3.8	7.5	8	7.4	6.8	6	7.1	2.8	7.4	6.1	4.2	4	4.8	4.7	C53
Ovary 1. Other female genital organs 0 Placenta 0 Kidney 2. Renal pelvis 0	.5	0.2	0.9	0.2	0.8	1.5	1.8	1.7	3.4	2.2	2.3	2.8	3.2	3.5	3.2	6	2.2	2.8	2.9	3.6	C54
Other female genital organs 0 Placenta 0 Kidney 2. Renal pelvis 0	.3	1.8	1	1.1	0	1.4	0.7	0.6	0.6	0.4	0.5	0.8	1.4	0.4	0.7	1.2	0.7	0.7	1.1	1.1	C55
Placenta 0 Kidney 2. Renal pelvis 0	.9	3.8	7.8	7	5.8	4.5	3.7	3.6	3.1	5.3	5	5.6	3.4	2.6	3.7	3.7	3	3.7	4.6	4.3	C56
Kidney     2.       Renal pelvis     0	1	0	0	0	0	0	0.2	0	0.1	0	0.5	0.8	0	0	0	0	0	0.3	0	0.2	C57
Renal pelvis 0		0.1	0.3	0.6	0.8	0.3	0	0.1	0.1	0	0.2	0.1	0	0.2	0	0.4	0.1	0	0	0.2	C58
	.3	1.2	1.7	1	1.8	2.2	0.7	2.2	0.6	2	0.8	1.2	4	1.7	1.5	3.1	1.2	2.3	2	2.3	C64
		0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	C65
Ureter 0		0	0	0	0	0.2	0	0	0	0.3	0	0	0	0	0.2	0	0.2	0	0	0	C66
Bladder 2.	.4	2.9	1.6	3.4	1.5	2.3	2.8	2	4.8	2.9	4.8	2.7	2.8	2	1.8	2	1.5	1.4	2	1.6	C67
Other urinary organs 0		0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0.2	0	0	0	C68
Eye 0.	.7	0.4	0.7	0.9	0.2	0.2	0.3	0.2	0.7	0.5	0.3	0.4	0.2	0.3	0.4	0.4	0.2	0.2	0.1	0	C69
Brain, nervous system 1.	.3	2.7	3	2.4	1.9	3.2	1.1	1.2	2.5	1.4	2.2	1.7	1.9	1.4	3	2.2	0.9	1.2	2	1.8	C70-72
Thyroid 7		7.4	6.8	5.9	4.3	7	6.3	5.9	4.8	6.6	6.9	5.7	5	6.7	5.2	9.1	7.7	12.2	10.3	14.3	C73
Adrenal gland 0		0.7	0.3	0.2	0.5	0.3	0.1	0.3	0.1	0	0.3	0	0.4	0.1	0	0.4	0.3	0.2	0.1	0.3	C74
Other endocrine 0		0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	C75
Hodgkin disease 2.	.1	0.7	0.5	2	1.9	0.8	1.2	1.6	0.6	1.7	0.7	1.5	2.6	1.8	1.4	3.3	1	2.2	1.5	1.6	C81
Non-Hodgkin lymphoma 3.	.1	6.4	3.9	3.3	5.4	5.1	4.5	5.4	10	6	4.5	6	5.8	5.7	7.9	7.4	4.5	5.4	4	7.1	C82-85,C96
Immunoproliferative diseases 0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0.2	C88
Multiple myeloma 1.		2.7	1.9	2.5	2.7	0.5	0.2	1.5	1.7	1.5	2.3	0.8	0.9	1.6	1.5	1	1.6	1.4	1	1.5	C90
Lymphoid leukaemia 1		1.3	2	1	1.3	1.7	1.3	1.7	2.3	1.8	2	1.5	2.4	1.1	1.7	1.5	1.9	1.6	2.1	1.9	C91
Myeloid leukaemia 1.		1.9	1	1.9	2.5	1.8	0.9	2.1	2.1	1.3	1.3	1.7	2.1	2.1	2.9	2	1.7	1.7	2.3	2.2	C92-94
Leukaemia unspecified 0.		0.1	0.6	0.4	0.7	1.2	1.6	1.8	0.7	0.1	0.2	1.2	0.5	0.5	0	0.3	0	0.2	0.5	0	C95
Myeloproliferative disorders 0.		0.1	0.5	0.4	0.7	0	0	0.3	0.7	0.4	0.2	0.4	0.3	0.5	0	0.3	0	0.2	0.5	0	MPD
		0	0.5	0	0	0	0	0.3	0	0.4	0	0.4	0.5		0	0	0	0	0		MDS
		0												0	2					0	
Other and unspecified 6.		07	8.9 97.4	6.6	4.5	3.8	5.4	4.4	7.1	6.5	6.6	7.3	2.6	2.9		3.7	1.5	2.6	2.2	2	0&U
All sites 82 All sites but C44 79	.7	8.7 97.1		92.7	90.2	86.6 83.3	73.9 72.4	83.5 81.1	120	105	108	101 98.8	104 99.4	97.4 92.6	100	115	92.9 89.5	99.6 95.7	100 97.4	109 104	ALL ALLbC44

#### **REGIONAL DISTRIBUTION**

#### **Regional Distribution of Cancer Cases 1996-2015**

The high frequency of cancers reported in Muscat (5,289 cases) could be biased since the majority of cancer cases are referred to the National Oncology Center in Muscat and patients or their relatives may provide a local address in Muscat rather than their original place of residence. (Table 14)

Governorate	Frequency	Percentage (%)
Muscat	5,289	25.2
Al - Batinah North	3,552	16.9
Ad - Dakhliyah	2,256	10.7
Dhofar	2,132	10.2
AI - Batinah South	2,093	10
Ash- Sharqiah South	1,471	7.0
Adh -Dhahirah	1,208	5.8
Ash - Sharqiyah North	1,168	5.6
Al- Buraymi	302	1.4
Musandam	205	1
AI - Wusta	118	0.6
Unknown	1,208	5.8
Total	21,002	

Table 14: Regional distribution of incident cases

#### Common Cancer in Oman

Over the 20 year period (1996-2015), breast cancer was the leading cancer among Omanis followed by Non-Hodgkin lymphoma, leukemia, colorectal and thyroid (Table 15).

Table 15: Five most common Cancer among Omanis (Males & Females) 1996-2015.

Topograghy	Frequency	Percentage (%)
Breast	2,280	10.9
Non-Hodgkin lymphoma	1,533	7.3
Leukemia	1,439	6.9
Colorectal	1,382	6.6
Thyroid	1,277	6.1




# COMMON CANCER IN OMANIS 1996-2015



#### **1.BREAST**

Breast cancer is the leading cancer among males and females in Oman and accounted for 10.9% of total malignancies among Omanis. This malignancy has quadrupled in Oman in 2015 (n=217) compared to 1996 (n=53) (Figure 8).

Figure 8: Trends of breast cancer 1996-2015



Between 1996 and 2015, there were 2,280 cases of breast cancer reported in Oman: 2181 in women and only 99 in men. The world ASR for breast cancer in Omani women was 20.8 per 100,000 females (Table 16).


Table 16: Gender distribution of breast cancer

Gender	Frequency	CR	ASR
Male	99	0.5	1.1
Female	2,181	11.5	20.8

CR = Crude rateASR = Age-standarized rate

#### **1.BREAST**


Infiltrating ductal carcinoma was the most frequent histopathological type accounting for 73.9% of all breast cancer (Figure 9).



#### Figure 9: Morphology of breast cancer 1996-2015



Governorate	Frequency
Muscat	894
Al - Batinah North	274
Ad - Dakhliyah	244
Dhofar	193
AI - Batinah South	173
Ash- Sharqiah South	113
Adh -Dhahirah	121
Ash - Sharqiyah North	118
AI- Buraymi	36
Musandam	12
AI - Wusta	6
Unknown	96



#### 2.NON-HODGKIN LYMPHOMA (NHL)

Non-Hodgkin lymphoma is the second most common malignancy among Omanis and accounted for 7.3% of total malignancies. NHL cases reported in Oman doubled in 2015 (n=122) compared to 1996 (n=62) (Figure 10).




Figure 10: Trends of Non-Hodgkin lymphoma 1996-2015

Between 1996 and 2015, there were 1533 cases of NHL reported in Oman: 932 in men and 601 in women. The world ASR by gender were 8.3 cases per 100,000 Omani males and 5.4 cases per 100,000 females (Table 18).

Table 18 : Gender distribution of NHL

Gender	Frequency	CR	ASR
Male	932	4.8	8.3
Female	601	3.2	5.4

CR = Crude rate

ASR = Age-standarized rate

## 2.NON-HODGKIN LYMPHOMA (NHL)

#### Figure 11: Morphology of NHL 1996-2015





Table 19 : Regional distribution of NHL


Governorate	Frequency
Muscat	327
Al - Batinah North	252
Ad - Dakhliyah	156
Dhofar	174
AI - Batin ah South	160
Ash- Sharqiah South	116
Adh -Dhahirah	98
Ash - Sharqiyah North	102
Al- Buraymi	26
Musandam	16
AI - Wusta	11
Unknown	95



#### **3.LEUKEMIA**

Leukemia is the third most common malignancy among Omanis and accounted for 6.85% of total malignancies. The total number of leukaemia cases reported in Oman more than doubled in 2015 (n=97) compared to 1996 (n=43) (Figure 12).

Figure 12: Trends of leukemia 1996-2015




Between 1996 and 2015, there were 1,439 cases of leukemia reported in Oman: 843 in men and 596 in women. The world ASR by gender were 5.6 cases per 100,000 Omani males and 3.9 cases per 100,000 females (Table 20).


Table 20 : Gender distribution of Leukemia

Gender	Frequency	CR	ASR
Male	843	4.33	5.6
Female	596	3.15	3.9

CR = Crude rate ASR = Age-standarized rate

## **3.LEUKEMIA**






Lymphoid leukemia accounted for 50% of all leukemia following by myeloid leukemia 39% (Figure 13).

#### Table 21 : Regional distribution of leukemia

Governorate	Frequency
Muscat	305
Al - Batinah North	238
Ad - Dakhliyah	207
Dhofar	149
AI - Batinah South	162
Ash- Sharqiah South	99
Adh -Dhahirah	111
Ash - Sharqiyah North	73
AI- Buraymi	19
Musandam	13
AI - Wusta	9
Unknown	54



#### **4.COLORECTAL**

Colorectal is the fourth most common malignancy among Omanis and accounted for 6.58% of total malignancies. There was an increase of more than four folds in the total number of cases in Oman in 2015 (n=148) compared to 1996 (n=28), (Figure 14).




Figure 14: Trends of colorectal 1996-2015


Between 1996 and 2015, there were 1,382 cases of colorectal cancer reported in Oman: 774 in men and 608 in women. The world ASR by gender were 8 cases per 100,000 Omani males and 6.3 cases per 100,000 females (Table 22).

Table 22 : Gender distribution of colorectal cancer

Gender	Frequency	CR	ASR
Male	774	3.9	8
Female	608	3.2	6.3

CR = Crude rate ASR = Age-standarized rate


#### **4.COLORECTAL**



Adenocarcinoma was the most frequent histopathological type accounting for 77% of all colorectal cancer (Figure 15).

Governorate	Frequency
Muscat	382
Al - Batinah North	203
Ad - Dakhliyah	137
Dhofar	166
AI - Batinah South	121
Ash- Sharqiah South	91
Adh -Dhahirah	75
Ash - Sharqiyah North	67
AI- Buraymi	19
Musandam	18
AI - Wusta	6
Unknown	97






#### **5.THYROID**

Thyroid is the fifth most common malignancy among Omanis and accounted for 6.08% of total malignancies. There was a four-fold increase in the total cases of thyroid cancer reported in Oman in 2015 (n=164) compared to 1996 (n=39), (Figure 16).

Figure 16: Trends of thyroid cancer 1996-2015



Between 1996 and 2015, there were 1,277 cases of thyroid cancer reported in Oman: 242 in men and 1,035 in women. The world ASR by gender were 2 cases per 100,000 Omani males and 7.6 cases per 100,000 females (Table 24).

Table 24: Gender distribution	of thyroid cancer
-------------------------------	-------------------


Gender	Frequency	CR	ASR
Male	242	1.2	2
Female	1,035	5.5	7.6

CR = Crude rate

ASR = Age-standarized rate

#### **5.THYROID**


#### Figure 17: Morphology of thyroid cancer 1996-2015



Papillary carcinoma was the most frequent histopathological type accounting for 83% of all thyroid cancer (Figure 17).

Governorate	Frequency
Muscat	319
AI - Batinah North	180
Ad - Dakhliyah	145
Dhofar	151
AI - Batinah South	112
Ash- Sharqiah South	104
Adh -Dhahirah	91
Ash - Sharqiyah North	72
Al- Buraymi	16
Musandam	9
AI - Wusta	2
Unknown	76

#### Table 25 : Regional distribution of thyroid cancer



# FIVE MOST COMMON CANCER AMONG FEMALES AND MALES IN OMAN



#### **COMMON CANCER IN MALES**

Between 1996 and 2015, prostate cancer was observed to be the leading malignancy in Omani males (998 new cases), followed by cancers of the stomach, NHL, leukemia, and colorectal. Table 26 summarizes the five most common cancers in Omani male in three different periods 1996-2005, 2006-2015 and finally over 20 years 1996-2015.

Table 26 : Five most common cancer among males in Oman

Years 1996-2005	
Topography	Frequency
Stomach	492
Non-Hodgkin lymphoma	431
Leukemia	385
Prostate	382
Lung	360
Years 2006-2015	
Topography	Frequency
Prostate	616
Colorectal	534
Non-Hodgkin lymphoma	501
Stomach	468
Leukemia	458
Years 1996-2015	
Topography	Frequency
Prostate	998
Stomach	960
Non-Hodgkin lymphoma	932
Leukemia	843
Colorectal	774

#### **1.PROSTATE**

Prostate cancer was the leading cancer in Omani males between 1996 and 2015 and accounting for 9.3% of all incident cancers in males with an average annual ASR of 11.6 /100,000 people. The trend of prostate cancer incidence continued to rise slowly over the years; the lowest ASR (6.9/100,000) was reported in 2003 and the highest (17/100,000) in 2011. Age-specific incidence among males begins in the 40-45 year age group and steadily rises to peak in the 70-74 year age group (Figure 18 and Figure 19).





Figure 18: Age specific incidence rate for prostate cancer among Omani male 1996-2015

Figure 19: Age-Standardized Incidence Rates for Prostate Cancer in Omani Males





#### 2.STOMACH

Stomach cancer was the second most common cancer in Omani males between 1996 and 2015 and accounting for 8.95% of all incident cancers in males with an average annual ASR of 10.9/100,000 male. The trend of stomach cancer incidence had declined over the years; the lowest ASR (5.7/100,000) was reported in 2015 and the highest (16.2/100,000) in 2005. Age-specific incidence among males begins in the 40-45 year age group and steadily rises to peak in the 55-70 year age group (Figure 20 and Figure 21).

Figure 20: Age specific incidence rate for stomach cancer among Omani male 1996-2015





Figure 21: Age-Standardized Incidence Rates for Stomach Cancer in Omani Males



#### **3.NON-HODGKIN LYMPHOMA**

Non Hodgkin lymphoma was the third most common male cancer and accounted for 8.7% of all incident cancer cases in Omani males. The average annual ASR was 8.3/100,000 male. There was a minor decrease in the ASR trend observed from 1996 to 2015; the lowest ASR (7.1/100,000) was reported in 2002 and the highest (11.3/100,000) in 2004. Age-specific incidence among males begins in the 30-35 year age group and gradually rises to peak in the 65-70 year age group (Figure 22 and Figure 23).





Figure 22: Age specific incidence rate for NHL among Omani male 1996-2015

Figure 23: Age-Standardized Incidence Rates for NHL in Omani Males



#### **4.LEUKEMIA**

Leukemia is the fourth most common cancer in males and accounted for 7.86% of all incident cancers in males with an average annual ASR of 5.6/100,000 male. The trend of leukemia incidence has slowly increased over the years; the lowest ASR (3.9/100,000) was reported in 1996 and the highest (9.9/100,000) in 2011. Age-specific incidence among males begins in the 0-10 year age group and gradually rises to peak in the 55-60 year age group (Figure 24 and Figure 25).





Figure 24: Age specific incidence rate for leukemia among Omani male 1996-2015

Figure 25: Age-Standardized Incidence Rates for leukemia in Omani Males



#### **5.COLORECTAL**

Colorectal cancer is the fifth most common cancer in males and accounted for 7.2% of all incident cancers in males with an average annual ASR of 8/100,000 male. The trend of colorectal cancer incidence continued to rise steadily over the years; the lowest ASR (3.3/100,000) was reported in 1999 and the highest (12/100,000) in 2015. Age-specific incidence among males begins in the 25- 30 year age group and steadily rises to peak in the 60-65 year age group (Figure 26 and Figure 27).

Figure 26: Age specific incidence rate for colorectal cancer among Omani male 1996-2015





Figure 27: Age-Standardized Incidence Rates for Colorectal in Omani Males



#### **COMMON CANCER IN FEMALES**

Between 1996 and 2015, breast cancer was the leading malignancy in Omani females with 2,181 new cases, followed by cancers of the, thyroid, colorectal, NHL and leukemia. Table 27 summarizes the five most common cancers among Omani female in three different periods 1996-2005, 2006-2015 and finally over 20 years 1996-2015.

Table 27: Five most cancer among females

Years 19	96-2005
Topography	Frequency
Breast	706
Thyroid	339
Cervix	267
Stomach	263
Leukemia	256
Years 20	06-2015
Topography	Frequency
Breast	1,475
Thyroid	696
Colorectal	442
Non-Hodgkin lymphoma	346
Leukemia	340
Years 19	96-2015
Topography	Frequency
Breast	2,181
Thyroid	1,035
Colorectal	608
Non-Hodgkin lymphoma	601
Leukemia	596

#### **1.BREAST**

Breast cancer is by far the most common female cancer and accounted for 21.2% of all incident cancer cases in Omani female between 1996 and 2015, with an average annual ASR of 20.8/100,000 people. Breast cancer incidence was observed to have an increasing trend over the 20-year period, the lowest ASR (13.2/100,000) was noted in 1998 and the highest (26.9/100,000) in 2015. The age-specific incidence rates among females begins in the 25- 30 year age group and steadily rises to peak in the 50-60 year (Figure 28 and Figure 29).

Figure 28: Age specific incidence rate for breast cancer among Omani female 1996-2015





Figure 29: Age-Standardized Incidence Rates for Breast cancer in Omani Females



#### 2.THYROID

Thyroid cancer was the second most common female cancer between 1996 and 2015 and accounted for 10% of all incident cancer cases in Omani female , with an average annual ASR of 7.6/100,000 people. The trend of thyroid cancer incidence continued to rise steadily over the years; the ASR was lowest (4.3/100,000) in 2000 and highest (14.3/100,000) in 2015. Cases were seen in females as young as 15 years of age, and incidence was found to increase with age, with peaks at 30-45 years and at 65-70 years (Figure 30 and Figure 31).





Figure 30: Age specific incidence rate for thyroid cancer among Omani female 1996-2015

Figure 31: Age-Standardized Incidence Rates for Thyroid cancer in Omani Females



Year

#### **3.COLORECTAL**

Colorectal cancer is the third most common cancer in females and accounted for 5.9% of all incident cancers in females with an average annual ASR of 7.3/100,000 female. The trend of colorectal cancer incidence continued to rise steadily over the years; the lowest ASR (1/100,000) was reported in 1999 and the highest (10/100,000) in 2014. Age-specific incidence among females begins in the 30- 35 year age group and steadily rises to peak in the 50-60 year age group (Figure 32 and Figure 33).




Figure 32: Age specific incidence rate for colorectal cancer among Omani female 1996-2015

Figure 33: Age-Standardized Incidence Rates for Colorectal in Omani Females



#### **4.NON-HODGKIN LYMPHOMA**

Non Hodgkin lymphoma was the fourth most common female cancer and accounted for 5.84% of all incident cancer cases in Omani females. The average annual ASR was 5.4/100,000 female. There was a gradual increase in the ASR trend observed from 1996 to 2015; the lowest ASR (3.1/100,000) was reported in 1996 and the highest (7.1/100,000) in 2015. Age-specific incidence among females begins in the 30-35 year age group and gradually rises to peak in the 55-60 year age group (Figure 34 and Figure 35).





Figure 34: Age specific incidence rate for NHL among Omani female 1996-2015

Figure 35: Age-Standardized Incidence Rates for NHL in Omani Females



Year

#### **5.LEUKEMIA**

Leukemia is the fifth most common cancer in females and accounted for 5.79% of all incident cancers in females with an average annual ASR of 3.9/100,000 female. The trend of leukemia incidence has slowly increased over the years; the lowest ASR (2.8/100,000) was reported in 1996 and the highest (5.6/100,000) in 2003. Age-specific incidence among females begins in the 0-10 year age group and gradually rises to peak in the 55-60 year and 70-75 age group (Figure 36 and Figure 37).





Figure 36: Age specific incidence rate for leukemia among Omani female 1996-2015

Figure 37: Age-Standardized Incidence Rates for Leukemia in Omani Females



# DISTRIBUTION OF CANCER BY GOVERNORATES

# Table 28: Distribution of cancer cases by governorates and gender 1996-2015

		1996-	1996-2005			2006-	2006-2015			1996	1996-2015	
Governorate	Male	%	Female	%	Male	%	Female	%	Male	%	Female	%
Muscat	1,013	21.0	1,031	24.9	1,373	23.3	1,872	30.5	2,386	22.3	2,903	28.2
AI - Batinah North	905	18.8	724	17.5	1,035	17.5	888	14.5	1,940	18.1	1,612	15.7
Ad - Dakhliyah	509	10.6	461	11.1	615	10.4	671	10.9	1,124	10.5	1,132	11.1
Dhofar	480	10.0	406	9.8	637	10.8	609	9.9	1,117	10.4	1,015	9.9
AI - Batinah South	522	10.8	467	11.3	562	9.5	542	8.8	1,084	10.1	1,009	9.8
Ash- Sharqiah South	406	8.4	319	7.7	413	7.0	333	5.4	819	7.6	652	6.4
Adh -Dhahirah	305	6.3	224	5.4	322	5.5	357	5.8	627	5.8	581	5.7
Ash - Sharqiyah North	298	6.2	227	5.5	311	5.3	332	5.4	609	5.7	559	5.4
Al- Buraymi	57	1.2	58	1.4	98	1.7	89	1.5	155	1.4	147	1.4
Musandam	72	1.5	33	0.8	65	1.1	35	0.6	137	1.3	68	0.7
AI - Wusta	21	0.4	16	0.4	46	0.8	35	0.6	67	0.6	51	0.5
Unknown	233	4.8	177	4.3	425	7.2	373	6.1	658	6.1	550	5.4
Total	4,821	100.00	4,143	100.00	5,902	100	6,136	100.0	10,723	100.0	10,279	100.00

## DISTRIBUTION

Muscat Table 29: Five most common cancer among females and males in Muscat Governorate

BreastStomachNHL266162139268162139Pars 206-2015139Pars 200-2015ThyroidPars 200246Pars 200 <th></th> <th></th> <th>Years 19</th> <th>Years 1996-2005</th> <th></th> <th></th>			Years 19	Years 1996-2005		
266     162     139       React     162     139       Breast <b>Years 2006-2015</b> Breast     Colorectal       Breast     280       280     246       Part All     246       Part All     11000       Part All     11000       Breast     11000	Site	Breast	Stomach	NHL	Leukemia	Lung
Years 2006-2015BreastColorectalThyroidBreastColorectalThyroid628280246FranceColorectalNHLBreastColorectalNHL	Frequency	266	162	139	127	106
BreastColorectalThyroid6282802467780246777 <th></th> <th></th> <th>Years 20</th> <th>06-2015</th> <th></th> <th></th>			Years 20	06-2015		
628 280 246 Years 1996-2015	Site	Breast	Colorectal	Thyroid	NHL	Leukemia
Years 1996-2015       Breast     Colorectal     NHL	Frequency	628	280	246	188	178
Breast Colorectal NHL			Years 19	96-2015		
	Site	Breast	Colorectal	NHL	Stomach	Thyroid
894 382 327	Frequency	894	382	327	322	319

AI Batinah North Table 30: Five most common cancer among females and males in AI Batinah North Governorate

		Years 19	Years 1996-2005		
Site	Stomach	NHL	Breast	Leukemia	Lung
Frequency	196	129	106	98	91
		Years 20	Years 2006-2015		
Site	Breast	Stomach	Colorectal	Leukemia	NHL
Frequency	168	147	148	140	123
		Years 19	Years 1996-2015		
Site	Stomach	Breast	NHL	Leukemia	Colorectal
Frequency	343	274	252	238	203

## **TOP FIVE CANCER**

Ad- Dakhliyah Table 31: Five most common cancer among females and males in Ad-Dhakhyliyah Governorate

KieLeukemiaNHLBreastStomachLiverFrequency10473696350 $Tacquency73696350TacrSton-2015TacrSton-201550SteeBreastLeukemiaThyroidColorectalNHLTacrTacr1031019683TacrStee1031019683TacrSteeSteeNHL9683SteeBreastLeukemiaNHL7083TacrSteeStee1031019683SteeSteeSteeStee1019683SteeSteeSteeStee1019683SteeSteeSteeSteeStee1019683SteeSteeSteeSteeStee1019683SteeSteeSteeSteeStee156145137$			Years 19	Years 1996-2005		
10473696363 $Rars 206-2015$ $Rars 200-2015$ $Rars 200-2015$ $Rars 200-2016$ $Rars 200-2016$ $Rars 175$ $103$ $101$ $96$ $Rars 200-2015$ $Rars 200-2015$ $Rars 200-2015$ $Rars 10$ $R$	Site	Leukemia	NHL	Breast	Stomach	Liver
Years 2006-2015Parse 2006-2015ColorectalData BreastLeukemiaThyroidData Breast10310196Data BreastYears 1996-2015145Data Std207156145	Frequency	104	73	69	63	50
BreastLeukemiaThyroidColorectal17510310196AYears 1996-201511BreastLeukemiaNHLThyroid244207156145			Years 20	06-2015		
175         103         101         96           A         Years 1996-2015         96         1           Breast         Leukemia         NHL         Thyroid           244         207         156         145	Site	Breast	Leukemia	Thyroid	Colorectal	NHL
Years 1996-2015BreastLeukemiaNHLThyroid244207156145	Frequency	175	103	101	96	83
BreastLeukemiaNHLThyroid244207156145			Years 19	<b>96-2015</b>		
244 207 156 145	Site	Breast	Leukemia	NHL	Thyroid	Colorectal
	Frequency	244	207	156	145	137

AI Batinah South Table 32: Five most common cancer among females and males in AI Batinah South Governorate

		Years 19	Years 1996-2005		
Site	Stomach	NHL	Leukemia	Breast	Lung
Frequency	87	77	76	60	57
		Years 20	Years 2006-2015		
Site	Breast	Leukemia	NHL	Colorectal	Stomach
Frequency	113	86	83	80	69
		Years 19	Years 1996-2015		
Site	Breast	Leukemia	NHL	Stomach	Colorectal
Frequency	173	162	160	156	121

## **TOP FIVE CANCER**

Dhofar Table 33: Five most common cancer among females and males in Dhofar Governorate

		Years 19	Years 1996-2005		
Site	NHL	Breast	Stomach	Leukemia	Thyroid
Frequency	72	68	68	67	56
		Years 20	Years 2006-2015		
Site	Breast	Colorectal	NHL	Thyroid	Leukemia
Frequency	125	111	102	95	82
		Years 19	Years 1996-2015		
Site	Breast	NHL	Colorectal	Thyroid	Leukemia
Frequency	193	174	166	151	149

Ash Sharqiah North Table 34: Five most common cancer among females and males in Ash Sharqiah North Governorate

		Years 19	Years 1996-2005		
Site	NHL	Stomach	Skin	Breast	Lung
Frequency	58	38	37	36	36
		Years 20	Years 2006-2015		
Site	Breast	Thyroid	NHL	Colorectal	Stomach
Frequency	82	50	44	42	40
		Years 19	Years 1996-2015		
Site	Breast	NHL	Stomach	Leukemia	Thyroid
Frequency	118	102	78	73	72

## **TOP FIVE CANCER**

Ash Sharqiah South Table 35: Five most common cancer among females and males in Ash Sharqiah South Governorate

		Years 19	Years 1996-2005		
Site	Stomach	Thyroid	Leukemia	Breast	NHL
Frequency	80	53	52	46	46
		Years 20	Years 2006-2015		
Site	NHL	Breast	Stomach	Colorectal	Thyroid
Frequency	70	67	66	53	51
		Years 19	Years 1996-2015		
Site	Stomach	NHL	Breast	Thyroid	Leukemia
Frequency	146	116	113	104	66

Adh Dhahirah Table 36: Five most common cancer among females and males in Adh Dhariah Governorate

		Years 19	Years 1996-2005		
Site	NHL	Leukemia	Breast	Prostate	Colorectal
Frequency	50	45	41	33	30
		Years 20	Years 2006-2015		
Site	Breast	Leukemia	Thyroid	NHL	Colorectal
Frequency	80	66	66	48	45
		Years 19	Years 1996-2015		
Site	Breast	Leukemia	NHL	Thyroid	Colorectal
Frequency	121	111	98	91	75

#### **TOP FIVE CANCER**

Al-Buraymi Table 37: Five most common cancer among females and males in Al Buraymi Governorate

		Years 19	Years 1996-2005		
Site	Breast	NHL	Skin	Thyroid	Colorectal
Frequency	11	10	6	8	6
		Years 20	Years 2006-2015		
Site	Breast	Skin	NHL	Colorectal	Leukemia
Frequency	25	18	16	13	13
		Years 1	Years 1996-2015		
Site	Breast	Skin	NHL	Colorectal	Leukemia
Frequency	36	27	26	19	19

Musandam Table 38: Five most common cancer among females and males in Musandam Governorate

		Years 19	Years 1996-2005		
Site	Stomach	Leukemia	Esophagus	Colorectal	Breast
Frequency	24	8	7	9	5
		Years 20	Years 2006-2015		
Site	Stomach	Colorectal	NHL	Breast	Prostate
Frequency	23	12	10	7	7
		Years 19	Years 1996-2015		
Site	Stomach	Colorectal	NHL	Leukemia	Breast
Frequency	47	18	16	13	12

## **TOP FIVE CANCER**

AI- Wusta Table 39: Five most common cancer among females and males in AI Wusta Governorate

		Years 19	Years 1996-2005		
Site	Liver	Bladder	NHL	Breast	Leukemia
Frequency	5	4	4	3	3
		Years 20	Years 2006-2015		
Site	Stomach	Bladder	NHL	Colorectal	Leukemia
Frequency	10	8	7	6	6
		Years 19	Years 1996-2015		
Site	Bladder	Stomach	NHL	Leukemia	Liver
Frequency	12	12	11	6	8

## **TOP FIVE CANCER**



See the difference

# MAKE OVERALL SURVIVAL PERSONAL

# In locally advanced squamous cell carcinoma of the head and neck

- Median overall survival of 49.0 months with ERBITUX® plus radiation therapy versus 29.3 months with radiotherapy alone<sup>1</sup>
- While maintaining quality of life<sup>2</sup>

1. Bonner JA et al. N Engl J Med 2006; 354:567–578. 2. Curran D et al. J Clin Oncol 2007; 25:2191–2197.

